[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1446
1. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol; 2005 Aug 20;23(24):5795-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
  • This study is based on the European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease.
  • RESULTS: Initial resistance was recorded for 116 (12%) of 934 assessable patients and was independently predicted by the presence of lung and absence of liver metastases, low hemoglobin level, and high granulocyte count.
  • Among 818 patients who were alive and progression free at 3 months, 347 subsequent progressions were recorded, and late resistance was independently predicted by high baseline granulocyte count, primary tumor outside of the stomach, large tumor size, and low initial imatinib dose.
  • [MeSH-minor] Adult. Aged. Benzamides. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Imatinib Mesylate. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110036.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-29; United States / NCI NIH HHS / CA / 5U10 CA11488-34
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


2. Metcalfe MS, Mullin EJ, Maddern GJ: Hepatectomy for metastatic noncolorectal gastrointestinal, breast and testicular tumours. ANZ J Surg; 2006 Apr;76(4):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For other primary diseases, however, the overall number of cases is relatively small, and it is more difficult to derive clear guidelines.
  • This paper reviews the reported experience of hepatectomy for metastases from non-colorectal gastrointestinal primary cancers, breast cancer and testicular teratoma.
  • The data collected included the primary disease, the number of cases reported, the survival post-hepatectomy and any prognostic factors associated with outcome.
  • [MeSH-major] Breast Neoplasms / pathology. Gastrointestinal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Gastrointestinal Stromal Tumors / secondary. Gastrointestinal Stromal Tumors / surgery. Humans. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Male. Sarcoma / secondary. Sarcoma / surgery. Stomach Neoplasms / pathology. Teratoma / secondary. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681543.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 54
  •  go-up   go-down


3. Nanashima A, Sumida Y, Abo T, Tobinaga S, Takeshita H, Hidaka S, Yasutake T, Nagayasu T, Mine M, Sawai T: A modified grading system for post-hepatectomy metastatic liver cancer originating from colorectal carcinoma. J Surg Oncol; 2008 Oct 1;98(5):363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified grading system for post-hepatectomy metastatic liver cancer originating from colorectal carcinoma.
  • BACKGROUND AND OBJECTIVES: There is no appropriate grading system for prediction of survival of patients with metastatic liver cancer (MLC) from colorectal carcinoma.
  • METHODS: We compared predictive accuracies of survival of 121 Japanese MLC patients of five systems, including clinical risk score (CRS) proposed by Memorial-Sloan-Kettering-Cancer-Center, original H-number (OHN) by Japanese Society for Cancer of the Colon and Rectum, revised H-number (RHN) and Grade by the same society (GJSCCR), and our modified Grade (MGJSCCR) based on OHN and presence of primary lymph node metastasis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Japan. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Survival Analysis. Survival Rate


Advertisement
4. Iwatsuki M, Mimori K, Fukagawa T, Ishii H, Yokobori T, Sasako M, Baba H, Mori M: The clinical significance of vimentin-expressing gastric cancer cells in bone marrow. Ann Surg Oncol; 2010 Sep;17(9):2526-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of vimentin-expressing gastric cancer cells in bone marrow.
  • BACKGROUND: Expression of the mesenchymal marker gene vimentin (VIM) in gastric cancer is associated with a more aggressive form of the disease and poor prognosis.
  • Because epithelial mesenchymal transition (EMT) plays a critical role in the progression of gastric cancer, VIM expression was examined in the bone marrow (BM) of gastric cancer patients.
  • METHODS: BM samples from 437 gastric cancer patients were collected and analyzed by quantitative RT-PCR.
  • Expression of VIM protein in the primary lesions of resected gastric cancers was evaluated using immunohistochemistry.
  • Furthermore, induction of VIM expression by TGF-beta1 and hypoxia was evaluated in gastric cancer cells.
  • Though cancer cells in the primary lesions did not stain with VIM antibody, some of the cells invading the intratumoral vessels were strongly positive for VIM, but were negative for E-cadherin.
  • Hypoxic conditions and treatment with TGF-beta1 induced VIM expression and repressed E-cadherin in gastric cancer cells, coupled with an alteration of cellular morphology.
  • CONCLUSIONS: We found that gastric cancer cells undergo EMT in BM to survive and metastasize.
  • These findings suggest that isolated tumor cells have the potential to undergo EMT, which could increase the malignancy of gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Bone Marrow / metabolism. Liver Neoplasms / genetics. Peritoneal Neoplasms / genetics. RNA, Messenger / genetics. Stomach Neoplasms / genetics. Vimentin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anoxia / genetics. Anoxia / metabolism. Anoxia / pathology. Cadherins / genetics. Cadherins / metabolism. Case-Control Studies. Cell Proliferation. Epithelial-Mesenchymal Transition. Epithelium / metabolism. Epithelium / pathology. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Mesoderm / metabolism. Mesoderm / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Oxygen / metabolism. Prognosis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Transforming Growth Factor beta1 / genetics. Transforming Growth Factor beta1 / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20358301.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transforming Growth Factor beta1; 0 / Vimentin; S88TT14065 / Oxygen
  •  go-up   go-down


5. Limaye PB, Alarcón G, Walls AL, Nalesnik MA, Michalopoulos GK, Demetris AJ, Ochoa ER: Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest; 2008 Aug;88(8):865-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development.
  • Studies in rodent liver have shown that alterations in transcription factor expression determine lineage specification during fetal liver development and signify transdifferentiation of cells of the biliary compartment into 'oval' cells and eventually hepatocytes in adult liver.
  • We examined the cellular localization of hepatocyte- or BEC-associated transcription factors in human fetal and adult liver and in diseases in which transdifferentiation between hepatocytes and biliary cells may play a role.
  • In the normal adult human liver, hepatocyte nuclear factor (HNF)4 alpha and HNF6 appeared exclusively in hepatocytes; HNF1beta, HNF3alpha, and HNF3beta were observed only in BEC.
  • We further examined expression of transcription factors in massive hepatic necrosis and in specific types of chronic liver disease.
  • Similarly, HNF3beta that is expressed only in BEC in normal adult liver was also observed in hepatocytes in primary biliary cirrhosis and chronic biliary obstruction.

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1997 Feb;26(2):343-52 [9059956.001]
  • [Cites] Carcinogenesis. 1996 Oct;17(10):2143-51 [8895481.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):348-53 [9110297.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):905-9 [9327722.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):771-9 [9502419.001]
  • [Cites] Hepatology. 1998 Oct;28(4):980-5 [9755234.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):455-63 [9764994.001]
  • [Cites] Genes Dev. 2000 Feb 15;14(4):464-74 [10691738.001]
  • [Cites] Mech Dev. 2000 Mar 15;92(1):83-8 [10704889.001]
  • [Cites] Dev Dyn. 2000 Oct;219(2):131-42 [11002334.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1393-403 [11158324.001]
  • [Cites] Hepatology. 2001 Dec;34(6):1184-92 [11732008.001]
  • [Cites] Development. 2002 Apr;129(8):1819-28 [11934848.001]
  • [Cites] Development. 2002 Apr;129(8):1829-38 [11934849.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1695-703 [12000721.001]
  • [Cites] Mech Dev. 2003 Jan;120(1):81-7 [12490298.001]
  • [Cites] Semin Liver Dis. 2003 Nov;23(4):373-84 [14722814.001]
  • [Cites] Carcinogenesis. 1987 Nov;8(11):1737-40 [3664968.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1541-7 [2466557.001]
  • [Cites] Arch Pathol Lab Med. 1990 Apr;114(4):403-6 [2322100.001]
  • [Cites] J Cell Biol. 1994 Jul;126(1):223-33 [8027180.001]
  • [Cites] Histol Histopathol. 1995 Apr;10(2):433-56 [7599440.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1243-53 [7557877.001]
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):513-24 [7479372.001]
  • [Cites] Hepatology. 1996 Jan;23(1):62-70 [8550050.001]
  • [Cites] Hepatology. 2005 Mar;41(3):535-44 [15726663.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):944-7 [15959514.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):168-71 [16357531.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S45-53 [16447274.001]
  • [Cites] Hepatology. 2007 Mar;45(3):716-24 [17326146.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):286-300 [17559071.001]
  • [Cites] Cell. 1996 Feb 23;84(4):575-85 [8598044.001]
  • [Cites] Am J Pathol. 1996 Aug;149(2):439-48 [8701983.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • (PMID = 18574450.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / CA35373; United States / NIDDK NIH HHS / DK / KO8 5K08DK65880; United States / NCI NIH HHS / CA / R01 CA103958; United States / NCI NIH HHS / CA / CA103958-05; United States / NCI NIH HHS / CA / R01 CA103958-05; United States / NCI NIH HHS / CA / R01 CA035373; United States / NCI NIH HHS / CA / CA30241; United States / NCI NIH HHS / CA / R01 CA035373-26; United States / NIDDK NIH HHS / DK / K08 DK065880; United States / NCI NIH HHS / CA / CA035373-26
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS85375; NLM/ PMC2631390
  •  go-up   go-down


6. Barlow AD, Nakas A, Pattenden C, Martin-Ucar AE, Dennison AR, Berry DP, Lloyd DM, Robertson GS, Waller DA: Surgical treatment of combined hepatic and pulmonary colorectal cancer metastases. Eur J Surg Oncol; 2009 Mar;35(3):307-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of combined hepatic and pulmonary colorectal cancer metastases.
  • METHODS: Between 1997 and 2006 we assessed 19 patients with colorectal cancer metastases for combined liver and lung metastasectomy, of whom 16 patients underwent surgery.
  • RESULTS: Synchronous liver metastases were present in three out of 16 patients at time of diagnosis of the primary tumour, and one out of 16 patients had synchronous lung and liver metastases with the primary tumour.
  • Of those 12 patients who developed metachronous metastases five patients developed liver metastases first, one patient developed pulmonary metastases first, and six patients developed synchronous liver and lung metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Pneumonectomy. Retrospective Studies. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657377.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Kim HO, Hwang SI, Hong HP, Yoo CH: Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for metachronous hepatic metastases from gastric cancer.
  • Between January 2000 and February 2008, we retrospectively reviewed 7 cases for which RFA was performed for treating metachronous hepatic metastases after resection of the primary gastric adenocarcinoma.
  • Combination therapy such as systemic chemotherapy or hepatic arterial infusion chemotherapy adjuvant to RFA would more reasonable for treating hepatic metastases from gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Catheter Ablation / methods. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplasms, Second Primary / surgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542847.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Zhang HZ, Dong SX, Zhou ZX, Shao YF: [Outcome of surgical therapy for liver metastasis of colorectal cancer: analysis of 75 cases]. Zhonghua Yi Xue Za Zhi; 2007 Jun 5;87(21):1457-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of surgical therapy for liver metastasis of colorectal cancer: analysis of 75 cases].
  • OBJECTIVE: To explore the strategy to improve the long term survival of liver metastasis of colorectal cancer after surgical treatment.
  • METHODS: The clinical data of 75 patients with liver metastasis of colorectal cancer, 43 males and 32 females, aged 51.4, who received hepatectomy between January 1981 and November 2005, were analyzed.
  • RESULTS: The primary tumor site was colon in 39 cases, and rectum in 36 cases.
  • Liver metastasis was synchronous in 59 patients, and metachronous in 16 patients.
  • 45 patients received simultaneous liver and colorectal resection, 29 patients received metachronous resection, and 1 patient did not receive primary rectal cancer resection.
  • CONCLUSION: Surgical resection of liver metastasis of colorectal cancer significantly prolongs the survival time, and resection of all liver deposits and the extrahepatic disease is the most important factor influencing survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome


9. Ahmad A, Chen SL, Bilchik AJ: Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases. Arch Surg; 2007 Jun;142(6):526-31; discussion 531-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: Multimodal treatment consisting of repeated hepatectomy and adjuvant systemic chemotherapy for liver-confined recurrence of colorectal cancer can yield long-term survival comparable with that associated with primary hepatectomy.
  • SETTING: A prospective database at a tertiary referral cancer center.
  • PATIENTS: Review of 274 consecutive liver resections identified 64 patients who underwent resection of hepatic colorectal metastases without ablation followed by adjuvant irinotecan hydrochloride- or oxaliplatin-based systemic chemotherapy.
  • MAIN OUTCOME MEASURES: Median and 5-year overall and disease-free survival after primary and repeated hepatectomy.
  • Multivariate analysis showed that less than 1 year between colectomy and liver resection (P = .001), more than 3 metastases (P = .001), no repeated hepatectomy (P = .01), and lymph node-positive primary colon cancer (P = .02) were independently predictive of worse survival.
  • Of 28 patients (44%) with liver-confined recurrence, 19 (30%) underwent repeated hepatectomy; at median follow-up of 38 months, median and 5-year overall survival after repeated hepatectomy were 48 months and 44%, respectively.
  • In patients with recurrence, median and 5-year overall survival measured from primary hepatectomy were 70 months and 73%, respectively, with repeated hepatectomy vs 43 months and 43%, respectively, without repeated hepatectomy (P = .03).
  • CONCLUSION: Multimodal treatment of recurrent colorectal cancer confined to the liver should begin with consideration of repeated hepatectomy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Camptothecin / analogs & derivatives. Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17576888.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Gorgun E, Remzi FH, Manilich E, Preen M, Shen B, Fazio VW: Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study. Surgery; 2005 Oct;138(4):631-7; discussion 637-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study.
  • BACKGROUND: The outcome of restorative proctocolectomy in the setting of chronic ulcerative colitis complicated by primary sclerosing cholangitis (PSC) is not clear.
  • The purpose of this study was to determine the surgical outcome, risk of dysplasia/cancer, morbidity/mortality, long-term results, and functional and quality of life results in patients with inflammatory bowel disease (IBD) and PSC who underwent restorative proctocolectomy with ileal pouch-anal anastomosis and compare them in a case-matched study.
  • Postoperative morbidity, incidence of neoplasia/cancer in the resected specimen, pouchitis, pouch failure, long-term mortality, and 5-year survival rates were compared between the groups.
  • A higher incidence of cancer (14% vs 5%, P = .02) and dysplasia in the resected specimen (40% vs 7%, P < .001), an associated increased risk of postoperative pelvic sepsis (14% vs 5%, P = .02), and higher long-term mortality (35% vs 4%, P < .001) were found in the PSC group compared with control group with no associated PSC.
  • The majority, 13 of 23 (57%), of the deaths in the PSC group were a result of liver disease.
  • CONCLUSIONS: PSC-associated IBD patients after restorative proctocolectomy have a higher risk of neoplasia/cancer in the resected specimen, postoperative pelvic sepsis, and higher long-term mortality.
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Infection / etiology. Intestinal Neoplasms / etiology. Male. Middle Aged. Pelvis. Quality of Life. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269291.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Gu YK, Fan WJ, Huang JH, Zhang L, Gao F: [Efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer]. Ai Zheng; 2007 Oct;26(10):1112-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer].
  • BACKGROUND & OBJECTIVE: Lung is the most common organ to which liver cancer cells transfer.
  • For the patients only with lung metastases whose primary liver cancers were in good control, treatment efficacy on lung metastasis is a crucial prognosis factor.
  • This study was to evaluate the efficacy of CT-guided intra-tumoral dehydrated ethanol injection on lung metastasis from liver cancer.
  • 2006, 17 patients with 37 lung metastatic lesions, whose primary liver cancers were in good control after operation or transcatheter artery chemoembolization (TACE), received CT-guided intra-tumoral dehydrated ethanol injection at Cancer Center of Sun Yat-sen University.
  • All primary liver cancers were in good control during follow-up.
  • CONCLUSION: CT-guided intra-tumoral dehydrated ethanol injection in treating lung metastasis from liver cancer is an effective, micro-invasive method with few complications.
  • [MeSH-major] Ethanol / therapeutic use. Liver Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemoembolization, Therapeutic / methods. Female. Humans. Injections, Intralesional. Iodized Oil. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927883.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3K9958V90M / Ethanol; 8001-40-9 / Iodized Oil
  •  go-up   go-down


12. Ye Y, Xie X, Yu J, Zhou L, Xie H, Jiang G, Yu X, Zhang W, Wu J, Zheng S: Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol; 2010 Jul;30(4):546-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Local production of cytokines within the liver may play a pivotal role in the regulation of pathophysiological processes during inflammation.
  • The purpose of this study was to quantify intrahepatic expression of Th1, Th2, Th17, and Treg-associated cytokines or transcription factors in patients with acute hepatitis B or chronic hepatitis B (CHB) and to analyze their relative roles in the promotion and regulation of hepatitis B virus (HBV)-associated liver diseases.
  • METHODS: Distribution and expression of IL-17, IFN-gamma, IL-4, Foxp3, and other cytokines in liver tissues were detected by immunohistochemistry and real-time quantitative PCR.
  • Patients with hepatitis B were compared with patients with chronic hepatitis C, primary biliary cirrhosis, alcoholic liver cirrhosis, and healthy controls.
  • RESULTS: The frequencies of intrahepatic IL-17 and IFN-gamma-producing cells in patients with HBV-associated liver dysfunction were much higher than that of IL-4 and Foxp3-positive cells.
  • There are more IL-17-producing cells than IFN-gamma-producing cells accumulating in the liver with severe hepatocellular damage.
  • Liver IL-17-producing cell infiltration was positively associated with the grade of liver inflammation in CHB and positively correlated to intrahepatic IL-8 expression (r=0.801, p<0.01) or neutrophil infiltration (r=0.917, p<0.01).
  • Inappropriate, excessive, and non-specific Th17 and Th1 effector responses may be involved in the pathogenesis of HBV-associated liver inflammation and hepatocellular damage.
  • Th17 response, especially, may exacerbate the inflammatory processes leading to liver failure.
  • IL-17-mediating liver neutrophil recruitment via induction of IL-8 may be one potential mechanism of liver injury in patients with hepatitis B.
  • An improved understanding of the factors that influence the differentiation and function of these cell types in vivo will be of great importance to the future development of immune therapies in HBV-associated liver disease.
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. Case-Control Studies. Cytokines / biosynthesis. Female. Humans. Liver / immunology. Liver / metabolism. Male. Middle Aged. T-Lymphocytes, Regulatory / immunology. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2005 Aug;79(15):9369-80 [16014900.001]
  • [Cites] Annu Rev Immunol. 1995;13:251-76 [7612223.001]
  • [Cites] Int Rev Immunol. 1998;16(5-6):541-51 [9646176.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3494-502 [18830757.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S13-21 [19399811.001]
  • [Cites] Hepatology. 2010 Jan;51(1):81-91 [19842207.001]
  • [Cites] Hepatology. 2009 Feb;49(2):646-57 [19177575.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Annu Rev Immunol. 1995;13:29-60 [7612225.001]
  • [Cites] Liver Int. 2006 Oct;26(8):912-9 [16953830.001]
  • [Cites] Annu Rev Immunol. 2009;27:485-517 [19132915.001]
  • [Cites] Hepatology. 1997 Apr;25(4):1022-7 [9096614.001]
  • [Cites] J Med Virol. 2003 Nov;71(3):376-84 [12966542.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6503-9 [10352265.001]
  • [Cites] Int Arch Allergy Immunol. 2001 Nov;126(3):179-84 [11752873.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S45-55 [19399792.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):598-607 [17692984.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):3025-33 [9185527.001]
  • [Cites] Annu Rev Immunol. 2009;27:147-63 [19302037.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):215-29 [15738952.001]
  • [Cites] Clin Liver Dis. 2007 Nov;11(4):727-59, vii-viii [17981227.001]
  • [Cites] Hepatology. 1995 Jul;22(1):61-8 [7601434.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Hepatol Res. 2007 Apr;37(4):248-54 [17397512.001]
  • [Cites] Antivir Ther. 1998;3(Suppl 3):13-24 [10726052.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2010-7 [19244111.001]
  • [Cites] Clin Microbiol Infect. 2005 Jan;11(1):52-6 [15649304.001]
  • [Cites] J Autoimmun. 2009 Feb;32(1):43-51 [19101114.001]
  • [Cites] J Hepatol. 2009 May;50(5):980-9 [19329213.001]
  • [Cites] Nat Med. 2007 Feb;13(2):139-45 [17290272.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2347-52 [9973514.001]
  • [Cites] Immunol Rev. 2008 Jun;223:87-113 [18613831.001]
  • [Cites] Gastroenterology. 1999 Sep;117(3):645-52 [10464141.001]
  • (PMID = 20393789.001).
  • [ISSN] 1573-2592
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-17; 0 / Transcription Factors
  •  go-up   go-down


13. Floer M, Binion DG, Nelson VM, Manley S, Wellner M, Sadeghi S, Behmaram B, Sewell C, Otterson MF, Kucharzik T, Rafiee P: Role of MutS homolog 2 (MSH2) in intestinal myofibroblast proliferation during Crohn's disease stricture formation. Am J Physiol Gastrointest Liver Physiol; 2008 Sep;295(3):G581-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Control and CD bowel tissues were used to generate primary cultures of muscularis mucosa myofibroblasts, which were assessed directly or following stimulation with TNF-alpha/LPS or H2O2.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2008 Jan;128(1):203-13 [17611581.001]
  • [Cites] Gut. 2007 Jan;56(1):130-9 [17172588.001]
  • [Cites] Ann Rheum Dis. 2000 May;59(5):386-9 [10784522.001]
  • [Cites] Free Radic Biol Med. 2000 Nov 1;29(9):881-8 [11063913.001]
  • [Cites] Genes Dev. 2001 Mar 15;15(6):724-36 [11274057.001]
  • [Cites] Inflamm Bowel Dis. 2001 Aug;7(3):226-36 [11515849.001]
  • [Cites] Atherosclerosis. 2002 Mar;161(1):17-26 [11882313.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] Am J Epidemiol. 2002 Nov 15;156(10):885-902 [12419761.001]
  • [Cites] BMC Gastroenterol. 2001;1:5 [11481030.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):2214-20 [12574395.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8508-15 [12496258.001]
  • [Cites] Thromb Haemost. 2003 Mar;89(3):530-7 [12624638.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Apr;305(1):78-85 [12649355.001]
  • [Cites] Free Radic Biol Med. 2003 Dec 15;35(12):1679-87 [14680690.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):325-33 [15060836.001]
  • [Cites] Coron Artery Dis. 2004 Aug;15(5):251-8 [15238821.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):257-65 [3335305.001]
  • [Cites] Dis Colon Rectum. 1990 Apr;33(4):271-6 [2323275.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):87-90 [2020666.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Aug 5;225(1):186-90 [8769115.001]
  • [Cites] J Biol Chem. 1998 Jul 31;273(31):19895-901 [9677427.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11301-6 [9736731.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Ann Rheum Dis. 2004 Dec;63(12):1695-9 [15547100.001]
  • [Cites] Semin Vasc Med. 2004 Nov;4(4):347-56 [15861311.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2724-9 [16393226.001]
  • [Cites] J Virol. 2007 Feb;81(3):1492-501 [17108035.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):439-48 [17156147.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 May;292(5):G1323-36 [17218473.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):137-49 [17631138.001]
  • [Cites] Heart. 2007 Aug;93(8):933-9 [17344325.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1692-8; dicussion 1698 [17940830.001]
  • [Cites] Respir Med. 2006 Feb;100(2):202-11 [16005622.001]
  • [Cites] World J Gastroenterol. 2006 Aug 14;12(30):4807-12 [16937461.001]
  • [Cites] J Mol Histol. 2006 Sep;37(5-7):301-7 [17080293.001]
  • [Cites] Dig Dis Sci. 2000 Feb;45(2):378-84 [10711455.001]
  • (PMID = 18635600.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK065948
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Lipopolysaccharides; 0 / MSH3 protein, human; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Tumor Necrosis Factor-alpha; AGG2FN16EV / Simvastatin; BBX060AN9V / Hydrogen Peroxide; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; VC2W18DGKR / Thymidine
  • [Other-IDs] NLM/ PMC2536780
  •  go-up   go-down


14. Sung JJ, Tsui SK, Tse CH, Ng EY, Leung KS, Lee KH, Mok TS, Bartholomeusz A, Au TC, Tsoi KK, Locarnini S, Chan HL: Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. J Virol; 2008 Apr;82(7):3604-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus.
  • [MeSH-minor] Adult. Aged. Amino Acid Substitution. Female. Genetic Markers. Genotype. Humans. Male. Middle Aged. Phylogeny. Point Mutation. Sequence Analysis, DNA. Sequence Homology. Viral Proteins / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Mar;118(3):554-9 [10702206.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):177-82 [18182659.001]
  • [Cites] J Med Virol. 2001 Jul;64(3):299-304 [11424118.001]
  • [Cites] J Med Virol. 2001 Oct;65(2):257-65 [11536231.001]
  • [Cites] J Viral Hepat. 2002 Mar;9(2):149-56 [11876799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6991-6 [12011457.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):175-81 [12210405.001]
  • [Cites] Hepatology. 2003 Jan;37(1):19-26 [12500184.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S491-6 [12534784.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):327-34 [12557138.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31745-55 [12799372.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5598-603 [14662947.001]
  • [Cites] Clin Infect Dis. 2004 May 1;38(9):1222-8 [15127332.001]
  • [Cites] Brief Bioinform. 2004 Jun;5(2):150-63 [15260895.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1593-8 [15090469.001]
  • [Cites] Gut. 2004 Oct;53(10):1494-8 [15361502.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):2023-32 [15180947.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S56-61 [15508104.001]
  • [Cites] J Mol Evol. 1980 Dec;16(2):111-20 [7463489.001]
  • [Cites] Lancet. 1981 Nov 21;2(8256):1129-33 [6118576.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] J Korean Med Sci. 1999 Aug;14(4):424-30 [10485623.001]
  • [Cites] Ann Hum Genet. 1956 May;20(4):309-11 [13314400.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):265-72 [15713961.001]
  • [Cites] J Infect Dis. 2005 Jun 15;191(12):2022-32 [15897987.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):65-73 [16391218.001]
  • [Cites] J Clin Microbiol. 2006 Mar;44(3):681-7 [16517839.001]
  • [Cites] Semin Liver Dis. 2006 May;26(2):153-61 [16673293.001]
  • [Cites] Hepatology. 2000 Mar;31(3):763-8 [10706570.001]
  • (PMID = 18216102.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Genetic Markers; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2268484
  •  go-up   go-down


15. Tarnowski M, Sieron AL: Adult stem cells and their ability to differentiate. Med Sci Monit; 2006 Aug;12(8):RA154-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult stem cells and their ability to differentiate.
  • This is a review of the current status of knowledge on adult stem cells as well as the criteria and evidence for their potential to transform into different cell types and cell lineages.
  • Reports on stem cell sources, focusing on tissues from adult subjects, were also investigated.
  • The question is still open about the characteristics of the primary stem cell.
  • Recent reports on cases of cancer in patients subjected to stem cell therapy are yet another controversial issue looked into in this review, although the pros and cons emerging from the results of published studies still do not provide satisfying evidence to fully understand this issue.
  • [MeSH-minor] Animals. Cell- and Tissue-Based Therapy. Humans. Liver Regeneration / physiology. Muscle, Skeletal / cytology. Nerve Tissue / cytology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865077.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 122
  •  go-up   go-down


16. Kim KH, Kim SH, Kim SH, Back JH, Park MJ, Kim JM: Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation. J Korean Med Sci; 2006 Dec;21(6):1064-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In PTC, COX-2 and iNOS were significantly overexpressed in patients over 45 yr of age (p=0.029, p=0.041), and iNOS expression was increased in patients with a large primary tumor (p=0.028).
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Thyroid. 1999 Feb;9(2):113-7 [10090309.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G688-96 [11518681.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] Ann Clin Lab Sci. 2001 Oct;31(4):325-48 [11688844.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):358-63 [11788675.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):238-42 [11889377.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):546-51 [11939728.001]
  • [Cites] Prostate. 2002 Nov 1;53(3):232-40 [12386924.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):331-40 [12665651.001]
  • [Cites] Histopathology. 2003 May;42(5):492-7 [12713627.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1604-10 [12738712.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):434-9 [12828608.001]
  • [Cites] Korean J Intern Med. 2003 Dec;18(4):225-9 [14717230.001]
  • [Cites] Histopathology. 2004 May;44(5):490-7 [15139997.001]
  • [Cites] Br J Pharmacol. 1993 Mar;108(3):833-7 [7682140.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1352-4 [7509718.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):727-30 [7531613.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2625-34 [9169492.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] BJU Int. 2000 Oct;86(6):736-41 [11069387.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):303-8 [11196178.001]
  • [Cites] Antioxid Redox Signal. 2001 Apr;3(2):231-48 [11396478.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):S35-9 [11442675.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2445-51 [9278337.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31138-48 [9388267.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Laryngoscope. 1999 Jan;109(1):148-52 [9917057.001]
  • (PMID = 17179688.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2721930
  •  go-up   go-down


17. Liu NN, Shen DL, Chen XQ, He YL: [Clinical analysis of 355 patients with bone metastasis of malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common primary tumors were lung cancer in men and breast cancer in women.
  • Among them, it was 34.9 months in prostate cancer and 4.6 months in hepatocellular carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / secondary. Combined Modality Therapy. Female. Humans. Liver Neoplasms / pathology. Male. Middle Aged. Pain / etiology. Pain Management. Prostatic Neoplasms / pathology. Quality of Life. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450589.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Iancu C, Mocan LC, Todea-Iancu D, Mocan T, Acalovschi I, Ionescu D, Zaharie FV, Osian G, Puia CI, Muntean V: Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer. J Gastrointestin Liver Dis; 2008 Sep;17(3):299-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer.
  • AIM: To identify the risk, the host-related prognostic factors and their predictive value for anastomotic leakage after colorectal resections following cancer.
  • METHOD: 993 patients who underwent large bowel resection and primary anastomosis above 12 centimeters from the anal verge, without a temporary or permanent stoma at the Surgical Hospital No.3 (Cluj-Napoca, Romania) were retrospectively reviewed.
  • CONCLUSION. A serum protein level lower than 5.5 g/dl and serum hemoglobin lower than 9.4 g/dl could be considered as host-related predictive markers for anastomotic leak in large bowel resections for cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / complications. Blood Proteins / analysis. Female. Hemoglobins / analysis. Humans. Hypoproteinemia / complications. Logistic Models. Male. Middle Aged. Postoperative Complications. Prognosis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836623.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Hemoglobins
  •  go-up   go-down


19. Ishizone S, Maruta F, Saito H, Koide N, Sugiyama A, Nakayama J, Miyagawa S: Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy; 2006;52(6):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
  • BACKGROUND: This study was designed to examine the efficacy and compliance of S-1 for the patients with peritoneal metastasis of gastric cancer.
  • METHODS: Sixteen consecutive patients with peritoneal metastasis of gastric cancer were treated with S-1.
  • We elucidated some factors to prolong the survival of the patients treated with S-1 for peritoneal metastasis: peritoneal metastasis without other distant metastases, the combination of S-1 treatment and gastrectomy, and low expression of thymidine phosphorylase mRNA in primary tumors.
  • CONCLUSIONS: S-1 showed a surprisingly long-term survival with minimum toxicity in patients with peritoneal metastasis of gastric cancer.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Dihydrouracil Dehydrogenase (NADP) / metabolism. Drug Combinations. Female. Gastrectomy. Humans. Intestinal Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Orotate Phosphoribosyltransferase / metabolism. Patient Compliance. Survival Rate. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008790.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


20. Jiao ZY, Gou CZ, Cao N, Li YM: [Correlation of tissue factor expression to angiogenesis of gastric carcinoma and its clinical significance]. Ai Zheng; 2005 Jul;24(7):880-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Tissue factor (TF), the primary physiologic initiator of coagulation cascade, is involved in the process of angiogenesis of various malignancies.
  • TF expression was correlated to the overall survival times of patients, TNM stage, and liver metastasis (P<0.05).
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Female. Follow-Up Studies. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Microcirculation / pathology. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004820.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factor A; 9035-58-9 / Thromboplastin
  •  go-up   go-down


21. Medine CN, Greenhough S, Hay DC: Role of stem-cell-derived hepatic endoderm in human drug discovery. Biochem Soc Trans; 2010 Aug;38(4):1033-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the safety evaluation process is hindered by the availability and quality of primary human liver models with which to study drug toxicity.
  • In an attempt to overcome this limitation, research has focused on deriving human hepatocytes from a number of sources, including progenitors from fetal and adult liver, human cell lines derived from liver tumours, immortalized human hepatocytes and pluripotent stem cells.
  • The major hurdles in developing scalable and high-fidelity human hepatocytes from hepatic cell lines and fetal and adult progenitors have been limited organ availability, homogeneous cell purification, short-term cell culture, and the rapid loss of hepatocyte phenotype and function in culture.
  • Moreover, stem-cell-derived hepatic endoderm displays many of the functional attributes of primary human hepatocytes.
  • Our research is now focused on developing defined culture systems and improving cell culture microenvironments in order to improve our understanding of the mechanisms regulating human liver development.
  • [MeSH-major] Drug Discovery / methods. Embryonic Stem Cells / physiology. Endoderm / physiology. Liver / embryology
  • [MeSH-minor] Adult. Cell Culture Techniques / standards. Humans. Induced Pluripotent Stem Cells / cytology. Induced Pluripotent Stem Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658999.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


22. Fiaschetti V, Fiori R, Gaspari E, Crusco S, Simonetti G: Mixed hepatoblastoma in a young male adult: a case report and literature review. Case Rep Med; 2010;2010:919457
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed hepatoblastoma in a young male adult: a case report and literature review.
  • Hepatoblastoma (HB) is a rare malignant tumour of the liver and usually occurs in the first three years of life.
  • Most of these tumours arise in the embryo; hence it seems to be unusual that hepatoblastoma occurs in adults and is an exceptional cause of primary malignant liver tumour in adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21113306.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2990241
  •  go-up   go-down


23. Zhang M, Li B, Yan LN, Yin F, Wen TF, Zeng Y, Zhao JC, Ma YK: Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B. World J Gastroenterol; 2008 Feb 28;14(8):1280-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.
  • METHODS: We retrospectively examined a cohort of 150 consecutive primary cadaveric liver transplants with HCC in our center over 6 years.
  • The predictive power of a new model and the model for end stage liver disease was compared by the receiver operating characteristic curve.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Hepatitis B / complications. Hepatitis B / therapy. Liver Neoplasms / etiology. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Cell Survival. Cohort Studies. Female. Humans. Liver Diseases / diagnosis. Liver Diseases / therapy. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies


24. Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL: Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer; 2007 Sep 3;97(5):582-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary end point was patient survival; secondary end points were the impact of therapy on tumour response, quality of life and variceal bleeding episodes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diarrhea / chemically induced. Female. Humans. Male. Middle Aged. Multivariate Analysis. Nausea / chemically induced. Neoplasm Staging. Octreotide / administration & dosage. Octreotide / adverse effects. Patient Compliance / statistics & numerical data. Prognosis. Quality of Life. Survival Analysis. Tamoxifen / administration & dosage. Tamoxifen / adverse effects. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998;77(1):115-22 [9459155.001]
  • [Cites] Digestion. 1996;57 Suppl 1:29-33 [8813463.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12(2):111-26 [9692685.001]
  • [Cites] Lancet. 1998 Jul 4;352(9121):17-20 [9800740.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1284-92 [10189133.001]
  • [Cites] Gut. 1999 Nov;45(5):766-74 [10517918.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1361-9 [15565568.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):694-701 [15763644.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1408-14 [15744746.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4338-46 [15994145.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1435-48 [16530734.001]
  • [Cites] Hepatology. 2007 Jan;45(1):9-15 [17187405.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):218-22 [10638587.001]
  • [Cites] Hepatology. 2000 Jan;31(1):54-8 [10613728.001]
  • [Cites] Am J Gastroenterol. 2007 Jul;102(7):1397-405 [17488248.001]
  • [Cites] Int J Oncol. 2000 Jun;16(6):1197-201 [10811995.001]
  • [Cites] J Hepatol. 2000 Nov;33(5):846-52 [11097497.001]
  • [Cites] Bull Cancer. 2000 Dec;87(12):881-6 [11174117.001]
  • [Cites] Mol Pathol. 2001 Jun;54(3):138-44 [11376124.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Z Gastroenterol. 2002 Jun;40(6):395-400 [12055662.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):903-7 [12066229.001]
  • [Cites] Hepatology. 2002 Sep;36(3):687-91 [12198662.001]
  • [Cites] Hepatogastroenterology. 2002 Sep-Oct;49(47):1245-50 [12239914.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S136-49 [12591191.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jun;129(6):327-34 [12811549.001]
  • [Cites] Acta Gastroenterol Belg. 2004 Jan-Mar;67(1):14-25 [15149081.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1474-84 [15196530.001]
  • [Cites] Gut. 2004 Aug;53(8):1180-9 [15247189.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):112-8 [15246216.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Endocrinology. 1992 Nov;131(5):2479-81 [1385103.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Aug 30;203(1):253-9 [8074663.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6334-7 [7987824.001]
  • [Cites] Hepatology. 1995 Jun;21(6):1535-42 [7768497.001]
  • [Cites] Gut. 1998 Mar;42(3):442-7 [9577356.001]
  • (PMID = 17687341.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 094ZI81Y45 / Tamoxifen; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2360361
  •  go-up   go-down


25. Oshima T, Kawasaki T, Ohashi R, Hasegawa G, Jiang S, Umezu H, Aoyagi Y, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M: Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis. Pathol Int; 2007 Feb;57(2):82-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis.
  • Liver metastases are the most critical prognostic factors for patients with colorectal carcinomas (CRC).
  • It has been reported that the dysregulation of hepatocyte nuclear factor-4alpha (HNF4alpha) expression is linked to the development of CRC, gastric cancer and hepatocellular carcinoma.
  • Immunohistochemically, P1, P2, MUC1 and CD10 expression were evaluated in 63 cases of primary CRC.
  • There was a relationship between the loss of P1 expression and metachronous liver metastases, and the survival rate of the P1-negative patients without liver metastasis at the time of the primary CRC resection tended to be worse than that of the P1-positive patients.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Colorectal Neoplasms / metabolism. Down-Regulation / physiology. Hepatocyte Nuclear Factor 4 / metabolism. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Mucin-1 / genetics. Mucin-1 / metabolism. Neprilysin / genetics. Neprilysin / metabolism. Prognosis. Promoter Regions, Genetic / genetics. Promoter Regions, Genetic / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300672.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HNF4A protein, human; 0 / Hepatocyte Nuclear Factor 4; 0 / Mucin-1; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


26. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R: Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer; 2009 Mar 1;115(5):1091-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
  • Anderson Cancer Center were reviewed, and their characteristics and survival were analyzed.
  • In univariate analysis, the factors that predicted shorter survival were primary tumor in the gastrointestinal tract; a history of thrombosis, liver metastases, and elevated levels of serum lactate dehydrogenase; platelet count; carbohydrate antigen 9 (Ca19-9) and Ca-125 levels; aspartate aminotransferase levels, and alkaline phosphatase levels (P < .05 for each).
  • In multivariate analysis, independent factors that predicted shorter survival were a history of thromboembolism (hazard ratio [HR], 2.38; 95% CI, 1.29-4.39; P = .005), platelets >or=440 x 10(9)/L (HR, 1.72; 95% CI, 1.12-2.65; P = .014), and the presence of liver metastases (HR, 1.51; 95% CI, 1.09-2.09; P = .013).
  • Patients with thrombocytosis, liver metastases, and a history of thromboembolism had worse outcomes.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [ErratumIn] Cancer. 2009 Apr 1;115(7):1588
  • (PMID = 19165805.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / RR024148
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST: Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg; 2008 Jan;12(1):183-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, 117 patients (56%) had unresectable HCC because of bilobar disease, poor liver function, and/or high medical risk for resection; whereas 92 patients (44%) underwent RFA as the primary treatment for small resectable HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Fine-Needle. Female. Follow-Up Studies. Hong Kong / epidemiology. Humans. Laparoscopy / methods. Male. Middle Aged. Morbidity / trends. Neoplasm Invasiveness. Retrospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Sep;232(3):381-91 [10973388.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1195-202 [8826940.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):616-28 [15965731.001]
  • [Cites] Dig Surg. 1999;16(6):459-67 [10805544.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):791-6 [13129558.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):122-30 [16012942.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1364-73 [16240062.001]
  • [Cites] Radiology. 2003 Jul;228(1):235-40 [12759473.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1201-9 [15690326.001]
  • [Cites] Eur Radiol. 2001;11(6):914-21 [11419162.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Gut. 2005 Aug;54(8):1151-6 [16009687.001]
  • [Cites] AJR Am J Roentgenol. 1996 Sep;167(3):759-68 [8751696.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1219-22 [8983610.001]
  • [Cites] Surg Oncol. 2005 Jul;14(1):41-52 [15777889.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] AJR Am J Roentgenol. 2006 May;186(5 Suppl):S316-21 [16632694.001]
  • [Cites] Arch Surg. 2006 Feb;141(2):181-90 [16490897.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):63-70 [11420484.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):500-7 [10931448.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1618-24 [8194710.001]
  • [Cites] N Engl J Med. 1996 Jun 13;334(24):1561-7 [8628336.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):440-7 [16470712.001]
  • (PMID = 17874276.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Hwang JP, Hassan MM: Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer; 2009;9:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation.
  • Anderson Cancer Center.
  • Timely hepatitis screening and interventions by primary care physicians may be the most logical solution to reduce the burden of hepatitis-associated HCC among Asian Americans.
  • [MeSH-major] Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / mortality. Hepatitis / complications. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Asian Americans. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Survival. alpha-Fetoproteins / metabolism


29. Kim JW, Kim YB, Kim NK, Min BS, Shin SJ, Ahn JB, Koom WS, Seong J, Keum KC: The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. Radiat Oncol; 2010;5:75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study.
  • BACKGROUND: Synchronous liver metastases are detected in approximately 25% of colorectal cancer patients at diagnosis.
  • The rates of local failure and distant metastasis are substantial in these patients, even after undergoing aggressive treatments including resection of primary and metastatic liver tumors.
  • The purpose of this study was to determine whether adjuvant pelvic radiotherapy is beneficial for pelvic control and overall survival in rectal cancer patients with synchronous liver metastasis after primary tumor resection.
  • METHODS: Among rectal cancer patients who received total mesorectal excision (TME) between 1997 and 2006 at Yonsei University Health System, eighty-nine patients diagnosed with synchronous liver metastasis were reviewed.
  • Thirty-six patients (58%) in group S and twenty patients (74%) in group S+R received local treatment for liver metastasis.
  • In a subgroup analysis of fifty-six patients who received local treatment for liver metastasis, the two-year PFFS were 64.9% and 82.9% (p = 0.05), respectively; the two-year OS were 74.1% and 80.0% (p = 0.616) in group S (n = 36) and group S+R (n = 20), respectively.
  • Rectal cancer patients with synchronous liver metastasis may benefit from adjuvant pelvic RT through an increased pelvic control rate and improved quality of life.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Liver Neoplasms / radiotherapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pelvis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Swiss Surg. 1996;Suppl 4:4-17 [8963836.001]
  • [Cites] Lancet. 1994 Jun 4;343(8910):1405-10 [7515134.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):107-16 [11163503.001]
  • [Cites] Surg Gynecol Obstet. 1970 Oct;131(4):697-700 [5458530.001]
  • [Cites] Am J Surg. 1978 Jan;135(1):81-5 [623377.001]
  • [Cites] Prog Clin Cancer. 1978;7:217-33 [360278.001]
  • [Cites] Arch Surg. 1984 Jun;119(6):647-51 [6732473.001]
  • [Cites] Cancer Metastasis Rev. 1984;3(4):303-24 [6394125.001]
  • [Cites] Ann Surg. 1987 Mar;205(3):264-70 [3827362.001]
  • [Cites] World J Surg. 1987 Aug;11(4):541-7 [3630198.001]
  • [Cites] Dis Colon Rectum. 1988 Jan;31(1):1-4 [3366020.001]
  • [Cites] Br J Surg. 1988 Jul;75(7):641-4 [3416116.001]
  • [Cites] Radiother Oncol. 1988 Dec;13(4):245-52 [3064191.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1105-12 [2045852.001]
  • [Cites] Semin Oncol. 1991 Aug;18(4):399-406 [1650502.001]
  • [Cites] Semin Oncol. 1991 Oct;18(5):411-20 [1925630.001]
  • [Cites] Dis Colon Rectum. 1999 May;42(5):632-9 [10344686.001]
  • (PMID = 20804559.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2941492
  •  go-up   go-down


30. Wallace MJ, Gupta S, Hicks ME: Out-of-plane computed-tomography-guided biopsy using a magnetic-field-based navigation system. Cardiovasc Intervent Radiol; 2006 Jan-Feb;29(1):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighteen patients had an underlying primary malignancy.
  • Target lesions were located in the adrenal gland (n = 7), liver (n = 6), pancreas (n = 3), lung (n = 2), retroperitoneal lymph node (n = 1), and pelvis (n = 1).
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328686.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, Hoffmann J, Csepregi A, Röcken C, Molnar B, Schulz HU, Malfertheiner P, Lofton-Day C: Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology; 2006 Nov;131(5):1418-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: The identification of novel genetic and epigenetic markers indicative of changes in the pathogenesis of colon cancer, along with easier-to-use, more sensitive assay methods, may improve the detection, treatment, and overall prognosis of this malignancy.
  • METHODS: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified.
  • Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.
  • ALX4 methylation was also analyzed in the serum of 30 patients with colon cancer.
  • RESULTS: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P < .0001).
  • In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P < .001).
  • ALX4 gene methylation was also more frequently found in sera of patients with colon cancer compared with noncancer controls (P < .0001).
  • CONCLUSIONS: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract.
  • ALX4 gene methylation in sera of patients with cancer may thus serve as a methylation-specific test for colon and other gastrointestinal cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Colonic Polyps / genetics. DNA Methylation. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Metastasis. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101318.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALX4 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors
  •  go-up   go-down


32. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A: Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol; 2008 Jul;9(7):621-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiofrequency ablation is an accepted treatment for non-surgical patients with liver cancer.
  • Diagnoses included non-small-cell lung cancer (NSCLC) in 33 patients, metastasis from colorectal carcinoma in 53 patients, and metastasis from other primary malignancies in 20 patients.
  • Primary endpoints were technical success (defined as correct placement of the ablation device into all tumour targets with completion of the planned ablation protocol), safety (including identification of treatment-related complications and changes in pulmonary function), and confirmed complete response of tumours (according to modified Response Evaluation Criteria in Solid Tumors).
  • Secondary endpoints were overall survival, cancer-specific survival, and quality of life.
  • Cancer-specific survival was 92% (78-98%) at 1 year and 73% (54-86%) at 2 years in patients with NSCLC, 91% (78-96%) at 1 year and 68% (54-80%) at 2 years in patients with colorectal metastases, and 93% (67-99%) at 1 year and 67% (48-84%) at 2 years in patients with other metastases.
  • Patients with stage I NSCLC (n=13) had a 2-year overall survival of 75% (45-92%) and a 2-year cancer-specific survival of 92% (66-99%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome


33. Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K: Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol; 2008;43(1):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risks and patterns of intrahepatic distant recurrence (IDR) of a single, primary HCC lesion after radiofrequency (RF) ablation were examined.
  • METHODS: Ninety patients with a single primary HCC lesion of less than 3 cm who had complete RF ablation were enrolled in the study.
  • [MeSH-major] Bile Duct Neoplasms / secondary. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / secondary. Catheter Ablation / methods. Liver Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Humans. Incidence. Japan / epidemiology. Magnetic Resonance Imaging. Male. Middle Aged. Proportional Hazards Models. Protein Precursors / blood. Prothrombin. Retrospective Studies. Risk Factors. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2004 Dec;40(6):1396-405 [15565571.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1714-23 [15578509.001]
  • [Cites] J Hepatol. 2000 Feb;32(2):269-78 [10707867.001]
  • [Cites] Hepatology. 1993 Jul;18(1):47-53 [7686879.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):122-30 [16012942.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):688-94 [9024706.001]
  • [Cites] AJR Am J Roentgenol. 2007 Feb;188(2):480-8 [17242258.001]
  • [Cites] Ann Surg. 1991 Aug;214(2):114-7 [1714267.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):225-37 [10728807.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1216-23 [11093727.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1501-8 [9118030.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):768-75 [7875479.001]
  • [Cites] Am J Surg. 1992 Feb;163(2):251-6 [1371207.001]
  • [Cites] Hepatol Res. 2005 Mar;31(3):172-7 [15792641.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] J Hepatol. 2003 Feb;38(2):200-7 [12547409.001]
  • [Cites] Hepatology. 1992 May;15(5):948-63 [1314774.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):488-94 [8392955.001]
  • [Cites] Cancer. 1987 Aug 15;60(4):810-9 [2439190.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1518-27 [17133456.001]
  • [Cites] Abdom Imaging. 2001 Jul-Aug;26(4):375-83 [11441549.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):321-8 [16495695.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):373-82 [11882759.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1682-90 [10547540.001]
  • [Cites] Hepatology. 1997 Jan;25(1):87-92 [8985270.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):913-9 [1310434.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):570-5 [11394657.001]
  • [Cites] Hepatology. 1992 Sep;16(3):694-701 [1324215.001]
  • [Cites] Eur J Radiol. 2006 Sep;59(3):432-41 [16690240.001]
  • [Cites] Cancer. 1994 May 15;73(10):2464-71 [7513601.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):949-56 [11251946.001]
  • (PMID = 18297439.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


34. van der Heide F, Dijkstra G, Porte RJ, Kleibeuker JH, Haagsma EB: Smoking behavior in liver transplant recipients. Liver Transpl; 2009 Jun;15(6):648-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking behavior in liver transplant recipients.
  • Long-term morbidity and survival after orthotopic liver transplantation (OLT) are to a large degree determined by cardiovascular disease and cancer.
  • All 401 adult patients with a follow-up of at least 2 years after OLT were included.
  • Tobacco use was the highest in patients with alcoholic liver disease (52% were active smokers before OLT, and 44% were after OLT) and the lowest in patients with primary sclerosing cholangitis (1.4% were active smokers before OLT).
  • No effect on skin cancer or cardiovascular disease was found.
  • [MeSH-major] Liver Transplantation. Smoking. Smoking Cessation
  • [MeSH-minor] Adolescent. Adult. Aged. Cholangitis, Sclerosing / surgery. Female. Follow-Up Studies. Graft Rejection / mortality. Graft Rejection / prevention & control. Health Surveys. Hepatitis C / surgery. Humans. Liver Cirrhosis, Biliary / surgery. Male. Middle Aged. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Survival Analysis. Young Adult


35. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB: Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation; 2006 Dec 27;82(12):1703-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma.
  • BACKGROUND: Sixty-five patients with unresectable hilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant chemoradiotherapy per a clinical care protocol developed in 1993.
  • Predictors of recurrence were older age, pretransplant cancer antigen (CA) 19-9 >100 U/ml, prior cholecystectomy, mass on cross-sectional imaging, residual tumor in explant >2 cm, tumor grade and perineural invasion in explant.
  • Underlying primary sclerosing cholangitis, percutaneous biliary intubation, gender, and other time points for CA 19-9 were not associated with recurrence.
  • Prolonged staging-to-OLT intervals for patients transplanted after implementation of model for end-stage liver disease (MELD) showed a trend toward increased recurrence.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / therapy. Liver Transplantation. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Risk Factors


36. Crowe DR, Eloubeidi MA, Chhieng DC, Jhala NC, Jhala D, Eltoum IA: Fine-needle aspiration biopsy of hepatic lesions: computerized tomographic-guided versus endoscopic ultrasound-guided FNA. Cancer; 2006 Jun 25;108(3):180-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic ultrasound-guided FNA (EUS-FNA), developed recently and used predominantly in evaluating mediastinal and pancreatic lesions, provides access to a significant portion of the liver and to perihepatic structures not readily accessible by a percutaneous approach.
  • METHODS: A recent experience (1997-2002) with CT-guided FNA of liver lesions at the University of Alabama Birmingham (UAB) was compared with the first 2.5 years of EUS-FNA experience (2000-2002).
  • RESULTS: In 6 years, 34 percutaneous CT-FNA liver biopsies were performed at UAB; in approximately 2.5 years, 16 EUS-FNA liver biopsies were done.
  • In both groups the primary clinical indication was suspected metastatic carcinoma (CT, 41% of cases vs. EUS, 56%).
  • Anatomy limits EUS-FNA to only a fraction of the hepatic parenchyma, but that fraction includes the hilum and left lobe of the liver and the proximal biliary tract.
  • [MeSH-major] Adenocarcinoma / pathology. Endosonography. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiography. Carcinoma, Hepatocellular / ultrasonography. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / radiography. Carcinoma, Neuroendocrine / ultrasonography. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / ultrasonography. Cholangiocarcinoma / pathology. Cholangiocarcinoma / radiography. Cholangiocarcinoma / ultrasonography. Female. Humans. Liver / pathology. Liver / radiography. Liver / ultrasonography. Male. Middle Aged. Tomography, X-Ray Computed


37. Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO: The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol); 2008 Feb;20(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of basal phenotype on the metastatic pattern of breast cancer.
  • AIMS: To assess whether basal phenotype influences the metastatic pattern and survival in patients with metastatic breast cancer.
  • MATERIALS AND METHODS: The basal phenotype status of a well-characterised series of consecutive primary operable breast cancers (1868 cases) was ascertained using the basal cytokeratin markers CK5/6 and CK14.
  • Follow-up data, including time, site and pattern of distant metastasis and post-metastasis survival, were available for 113 women with basal phenotype cancers and they were compared with 178 matching cases from women in the non-basal phenotype group.
  • There was no significant difference in the frequency of pleural or liver metastases between both groups.
  • The multivariate analysis, including other established prognostic variables in breast cancer, showed that basal phenotype is an independent poor prognostic factor.
  • CONCLUSION: Intrapulmonary and brain metastases are seen more frequently at metastatic presentation in basal phenotype breast cancer patients, and the basal phenotype is associated with a poorer survival after metastatic presentation.
  • Assessment of basal cytokeratin expression status may provide valuable prognostic information relevant to breast cancer patients' management.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Female. Humans. Keratin-14 / analysis. Keratin-5 / analysis. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981444.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-14; 0 / Keratin-5
  •  go-up   go-down


38. Etienne-Grimaldi MC, Formento JL, Francoual M, François E, Formento P, Renée N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res; 2008 Aug 1;14(15):4830-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
  • EXPERIMENTAL DESIGN: This study was conducted on 93 stage IV colorectal cancer patients with unresectable measurable liver metastasis receiving 5-FU-leucovorin (56 men and 37 women; 77 cancer deaths).
  • Liver metastases (n = 93) along with primary tumors (n = 48) were analyzed for K-Ras mutations (codons 12 and 13), p53 mutations (exons 4-9), p53 polymorphism (codon 72), thymidylate synthase (TS) polymorphism (28-bp repeats including G>C mutation), methylenetetrahydrofolate reductase polymorphism (677C>T, 1298A>C), thymidylate synthase (TS) activity, dihydropyrimidine dehydrogenase activity, folylpolyglutamate synthase activity, and p53 protein expression.
  • Mutated primary tumors (16 of 48) matched perfectly with mutated metastases.
  • CONCLUSIONS: The present data indicate a perfect concordance of K-Ras mutations between primary and liver metastasis and suggest that any predictive and/or prognostic value of K-Ras mutations in treatments combining anti-EGFR monoclonal antibodies with 5-FU should be exclusively linked to the anti-EGFR agent.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / pathology. Male. Middle Aged. Neoplasm Metastasis. Polymorphism, Genetic


39. Bouancheau D, Buecher B, Jarry A, Simon B, Masson D, Cassagnau E, Hamelin R, Laboisse CL, Bézieau S, Denis MG: The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment. Cancer Lett; 2005 Jun 16;224(1):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment.
  • Peroxisome proliferator-activated receptor gamma (PPAR(gamma)) ligands inhibit cell growth of colorectal cancer cells in most experimental models, but no significant effect could be observed in patients with colorectal cancer.
  • We therefore, screened human colorectal tumors to determine the prevalence of the PPAR(gamma) K422Q loss-of-function mutation, recently identified in 50% of colonic cancer cell lines.
  • A sensitive allele-specific real-time amplification assay was developed and 170 colorectal primary tumors and 12 liver metastasis were analyzed.
  • We can therefore exclude this alteration as a mechanism of resistance to PPAR(gamma) ligands in patients with colon cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chromans / pharmacology. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Liver Neoplasms / genetics. Liver Neoplasms / secondary. PPAR gamma / genetics. Thiazolidinediones / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15911106.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / PPAR gamma; 0 / Thiazolidinediones; I66ZZ0ZN0E / troglitazone
  •  go-up   go-down


40. Peng N, Li L, Cai X, Tan S, Wu T: Liver stem/progenitor cells in the canals of Hering: cellular origin of hepatocellular carcinoma with bile duct tumor thrombi? Stem Cell Rev; 2010 Dec;6(4):579-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver stem/progenitor cells in the canals of Hering: cellular origin of hepatocellular carcinoma with bile duct tumor thrombi?
  • However, recent studies revealed that primary tumor might be small, even undetectable, and there was no histopathologic evidence of direct tumor invasion into bile duct wall in some patients.
  • (1) the canals of Hering (CoH) are the most likely origin of liver stem/progenitor cells (LSPCs) in adult livers;.
  • (2) similar signalling pathways may regulate self-renewal in LSPCs and liver cancer cells, and a substantial proportion of liver tumors may often originate from the transformation of LSPCs; and (3) liver cancer contains rare cells with stem cell-like properties, which could derive from malignant transformation of LSPCs.
  • Herein, we propose that HCC with BDTT, especially with small or undetectable primary lesion and/or no histopathologic evidence for bile duct invasion, might arise from LSPCs residing in the CoH and, possibly, some primary lesions are formed firstly within the intrahepatic biliary tree.
  • When "tumor thrombi" extends mainly along bile duct, there might be "BDTT" alone; when it invades into surrounding parenchyma, there might often be small "primary tumor" with "BDTT".
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Stem Cell Rev. 2011 Nov;7(4):1046
  • [Cites] Med Chir Dig. 1975;4(5-6):267-70 [173942.001]
  • [Cites] Int J Clin Pract. 2008 Aug;62(8):1212-8 [18479363.001]
  • [Cites] World J Gastroenterol. 2004 May 15;10 (10 ):1397-401 [15133842.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2542-56 [17570225.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1451-61 [18316609.001]
  • [Cites] Langenbecks Arch Surg. 2009 Nov;394(6):1033-9 [19421771.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10831-9 [18006828.001]
  • [Cites] Surgery. 2001 Jun;129(6):692-8 [11391367.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):592-5 [15245596.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G859-70 [16322088.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):249-60 [16395407.001]
  • [Cites] Gut. 2010 Feb;59(2):247-57 [19880964.001]
  • [Cites] Liver Int. 2009 Aug;29(7):955-65 [19490415.001]
  • [Cites] Surgery. 2000 Nov;128(5):779-83 [11056440.001]
  • [Cites] Histopathology. 2008 Jan;52(2):224-32 [18184271.001]
  • [Cites] World J Gastroenterol. 2005 Jul 7;11(25):3966-9 [15991304.001]
  • [Cites] Hepatology. 2008 Jan;47(1):288-95 [17929301.001]
  • [Cites] Dis Markers. 2008;24(4-5):223-9 [18525116.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] J Hepatol. 2010 Jan;52(1):117-29 [19913937.001]
  • [Cites] Arch Med Res. 2007 Aug;38(6):612-20 [17613352.001]
  • [Cites] J Pathol. 1997 Mar;181(3):330-7 [9155721.001]
  • [Cites] World J Surg. 2004 May;28(5):471-5 [15085398.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):937-50 [17673212.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):435-45 [11895858.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(1):27-34 [17290078.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):1012-24 [19150350.001]
  • [Cites] J Hepatol. 2000 Jul;33(1):76-84 [10905589.001]
  • [Cites] Dig Liver Dis. 2009 Jul;41(7):455-62 [19403350.001]
  • [Cites] Hepatology. 2010 Apr;51(4):1401-9 [20054870.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1320-1 [19826380.001]
  • [Cites] Gastroenterology. 2007 Nov;133(5):1579-91 [17983805.001]
  • [Cites] Hepatogastroenterology. 1994 Aug;41(4):349-54 [7959570.001]
  • [Cites] Histopathology. 1996 Apr;28(4):291-9 [8732337.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(2):204-9 [17384916.001]
  • [Cites] Cancer. 1982 May 15;49(10):2144-7 [6280834.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1388-96 [11684955.001]
  • [Cites] Br J Cancer. 2009 Jun 2;100(11):1765-70 [19436294.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Intern Med. 2006;45(5):229-33 [16595985.001]
  • [Cites] Hum Pathol. 2009 Sep;40(9):1304-11 [19386347.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Hepatol Res. 2005 May;32(1):52-7 [15888382.001]
  • [Cites] Hepatology. 2001 Mar;33(3):738-50 [11230756.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1425-33 [10573521.001]
  • [Cites] Eur J Radiol. 2010 Oct;76(1):103-9 [19501994.001]
  • [Cites] Hepatology. 1992 Dec;16(6):1327-33 [1280243.001]
  • [Cites] Hepatology. 2009 Sep;50(3):992-3 [19714715.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 May;134(5):535-41 [17917742.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Aug;135(8):1073-80 [19294418.001]
  • [Cites] Nat Med. 2006 Apr;12(4):410-6 [16532004.001]
  • [Cites] Hepatology. 2009 May;49(5):1655-63 [19309719.001]
  • [Cites] Ann N Y Acad Sci. 2009 Feb;1155:206-21 [19250206.001]
  • [Cites] Environ Health Perspect. 1993 Dec;101 Suppl 5:15-26 [7516873.001]
  • [Cites] Stem Cells. 2006 Aug;24(8):1852-8 [16627685.001]
  • [Cites] J Gastroenterol. 2002 Jan;37(1):55-8 [11824802.001]
  • [Cites] Eur J Cancer. 2010 Apr;46(6):1056-61 [20202823.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2800-5 [18539957.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4287-95 [18519688.001]
  • (PMID = 20809255.001).
  • [ISSN] 1558-6804
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Aloia TA, Zorzi D, Abdalla EK, Vauthey JN: Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection. Ann Surg; 2005 Aug;242(2):172-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection.
  • Saline-linked cautery is now widely used in liver surgery and is reported to decrease blood loss during liver transection, but data on its exact benefits are lacking.
  • METHODS: From a single institution, prospective liver surgery database, we identified 32 consecutive patients with noncirrhotic livers who underwent resection for primary or metastatic disease using a 2-surgeon technique with saline-linked cautery and ultrasonic dissection (SLC+UD) from December 2002 to January 2004.
  • From the same database, we identified a contemporary and matched set of 32 patients who underwent liver resection with similar indications using ultrasonic dissection alone (UD alone).
  • Postoperative liver function and complication rates were similar in each group.
  • CONCLUSIONS: The 2-surgeon technique for liver parenchymal transection using SLC and UD in noncirrhotic livers is safe and may provide advantages over other techniques.
  • [MeSH-major] Cautery / methods. Hemostatic Techniques. Hepatectomy / methods. Liver Neoplasms / surgery. Ultrasonic Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Retrospective Studies. Sodium Chloride

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1996 Jan;171(1):158-62 [8554132.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1563-5 [8298927.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):254-9; discussion 259-60 [9015167.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):322-30 [10077043.001]
  • [Cites] World J Surg. 1999 Oct;23(10):1032-7 [10512943.001]
  • [Cites] J Am Coll Surg. 2000 Jul;191(1):38-46 [10898182.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):155-62 [10903590.001]
  • [Cites] J Gastrointest Surg. 2002 Jul-Aug;6(4):569-74 [12127123.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):560-3 [12409660.001]
  • [Cites] Lancet. 2002 Dec 21-28;360(9350):2049-50 [12504404.001]
  • [Cites] Br J Surg. 2003 Jan;90(1):33-41 [12520572.001]
  • [Cites] World J Surg. 2004 Feb;28(2):166-72 [14708050.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):518-27 [15024313.001]
  • [Cites] Ann Surg. 2004 May;239(5):722-30; discussion 730-2 [15082977.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):596-600 [15239997.001]
  • [Cites] Ann Surg. 1974 Sep;180(3):285-90 [4368356.001]
  • [Cites] World J Surg. 1982 Jan;6(1):3-9 [7090393.001]
  • [Cites] Surgery. 1984 Feb;95(2):230-4 [6695340.001]
  • [Cites] Helv Chir Acta. 1992 Aug;59(2):437-42 [1428940.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):117-20 [8653334.001]
  • (PMID = 16041206.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride
  • [Other-IDs] NLM/ PMC1357721
  •  go-up   go-down


42. Buchler T, Freeman A, Harland S: Contralateral intratubular germ cell neoplasia in a patient with testicular cancer. Nat Clin Pract Urol; 2008 May;5(5):284-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contralateral intratubular germ cell neoplasia in a patient with testicular cancer.
  • INVESTIGATIONS: Measurement of serum levels of urea, electrolytes, liver enzymes, bilirubin, human chorionic gonadotropin, alpha-fetoprotein, lactate dehydrogenase, testosterone and luteinizing hormone, full blood count, and left testicular biopsy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Multiple Primary / pathology. Seminiferous Tubules / pathology. Seminoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Androgens / therapeutic use. Antineoplastic Agents / therapeutic use. Atrophy. Carboplatin / therapeutic use. Humans. Hypogonadism / diagnosis. Hypogonadism / therapy. Male. Orchiectomy. Testis / pathology. Testis / surgery. Testosterone / therapeutic use

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398407.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents; 3XMK78S47O / Testosterone; BG3F62OND5 / Carboplatin
  •  go-up   go-down


43. Yuan RH, Jeng YM, Chen HL, Hsieh FJ, Yang CY, Lee PH, Hsu HC: Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis. Clin Cancer Res; 2005 Apr 1;11(7):2568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: PAP and REG1A mRNA levels were measured in 265 surgically removed unifocal primary HCCs using reverse transcription-PCR.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Calcium-Binding Proteins / genetics. Carcinoma, Hepatocellular / pathology. Lectins, C-Type / genetics. Liver Neoplasms / pathology. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytoskeletal Proteins / genetics. Disease Progression. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Lithostathine. Male. Middle Aged. Mutation. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Survival Analysis. Trans-Activators / genetics. Tumor Suppressor Protein p53 / genetics. beta Catenin

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814635.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Calcium-Binding Proteins; 0 / Cytoskeletal Proteins; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / Nerve Tissue Proteins; 0 / REG1A protein, human; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


44. Sentani K, Oue N, Sakamoto N, Arihiro K, Aoyagi K, Sasaki H, Yasui W: Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach. Mod Pathol; 2008 Apr;21(4):464-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric cancer is one of the most common malignancies worldwide.
  • In this study, we screened for genes upregulated in gastric cancer by comparing gene expression profiles from serial analysis of gene expression and microarray and identified the palate, lung, and nasal epithelium carcinoma-associated protein (PLUNC) gene.
  • Immunostaining for PLUNC in 140 gastric cancer cases revealed strong and extensive staining of PLUNC in hepatoid adenocarcinoma of the stomach, whereas 7% of conventional gastric cancer cases showed focal immunostaining of PLUNC.
  • To investigate the utility of PLUNC immunostaining in the diagnosis of gastric hepatoid adenocarcinoma, six cases of gastric hepatoid adenocarcinoma (six primary tumors and two associated liver metastases) were studied further.
  • PLUNC staining was observed in all six primary hepatoid adenocarcinomas.
  • PLUNC staining was observed in both the hepatoid adenocarcinoma and tubular/papillary adenocarcinoma components of primary tumors, although PLUNC staining was preferentially localized in tubular/papillary adenocarcinoma components.
  • Staining of PLUNC was also detected in both liver metastases.
  • PLUNC staining was not observed in 52 cases of primary hepatocellular carcinoma or in normal adult or fetal liver.
  • These results indicate that PLUNC is a novel marker that distinguishes gastric hepatoid adenocarcinoma from primary hepatocellular carcinoma.
  • [MeSH-minor] Blotting, Western. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / metabolism. Diagnosis, Differential. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Liver Neoplasms / diagnosis. Liver Neoplasms / metabolism. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204429.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BPIFA1 protein, human; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Phosphoproteins
  •  go-up   go-down


45. Lepistö A, Kärkkäinen P, Järvinen HJ: Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis; 2008 Jun;14(6):775-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis.
  • BACKGROUND: This study aimed to determine the prevalence of primary sclerosing cholangitis (PSC) among patients with ulcerative colitis (UC) needing proctocolectomy.
  • Liver biopsy samples were taken at operation.
  • Only 19 of these had been diagnosed before surgery; 40 patients with PSC were detected by liver biopsy at the operation, making the sensitivity of perioperative liver biopsy to diagnose PSC 83.3%.
  • The cumulative incidence of colorectal dysplasia or cancer in the UC patients with PSC (19% after 10 years and 43% after 20 years) was not significantly different than that of UC patients without PSC (24% after 10 years and 39% after 20 years).
  • Liver biopsy can be recommended as a safe adjunct at proctocolectomy for surveillance of any liver effects.
  • [MeSH-minor] Adolescent. Adult. Aged. Anal Canal / surgery. Bile Duct Neoplasms / etiology. Bile Ducts, Intrahepatic. Biopsy. Cholangiocarcinoma / etiology. Female. Humans. Liver / pathology. Liver Transplantation. Male. Middle Aged. Pouchitis / etiology. Prevalence. Treatment Failure


46. Kotb HI, Fouad IA, Fares KM, Mostafa MG, Abd El-Rahman AM: Pharmacokinetics of oral tramadol in patients with liver cancer. J Opioid Manag; 2008 Mar-Apr;4(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of oral tramadol in patients with liver cancer.
  • BACKGROUND: There are no studies reported on pharmacokinetics of opioids in patients with hepatocellular carcinoma, the fifth most common cancer in the world.
  • METHODS: The authors have studied the pharmacokinetic profile of oral tramadol (50 mg) capsule in 20 patients with liver carcinoma (10 with primary carcinoma on top of chronic hepatitis C and 10 with secondary metastatic liver malignancy as a result of other primary) compared with 10 healthy controls.
  • RESULTS: Tramadol bioavailability showed a substantial increase in patients with primary liver cancer and secondary metastatic than that of control (98 percent, 75 percent, and 68 percent, respectively).
  • The area under the serum concentration-time curve increased significantly in patients with primary and metastatic cancer of liver than in control [1,933 microg/h/L (SD = 41), 1,327 microg/h/L (SD = 51), 1,138.5 microg/h/L (SD = 31), respectively].
  • Also, a significant difference in Cmax and Tmax was found between patients with malignant liver and control.
  • Reduced clearance and impaired elimination was significantly observed in patients with liver carcinoma than control.
  • Clearance was reduced to 50 percent of control, and elimination halflife increased up to three folds in patients with primary liver carcinoma than that of control.
  • CONCLUSION: It is recommended to lengthen the dose interval of oral tramadol, if it is to be used in patients with liver cancer for analgesic purposes, to 50 mg every 12 hours as it is proved to be effective and safe.
  • [MeSH-major] Analgesics, Opioid / pharmacokinetics. Liver Neoplasms / physiopathology. Pain, Intractable / drug therapy. Tramadol / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Biological Availability. Humans. Metabolic Clearance Rate. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18557166.001).
  • [ISSN] 1551-7489
  • [Journal-full-title] Journal of opioid management
  • [ISO-abbreviation] J Opioid Manag
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 39J1LGJ30J / Tramadol
  •  go-up   go-down


47. Neff R, Abdel-Misih R, Khatri J, Dignazio M, Garcia M, Petrelli N, Wilson P: The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors. Cancer Invest; 2008 Mar;26(2):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors.
  • The yttrium-90 radiation dose was dependent upon the percentage of tumor involvement of the liver, with a dose modification (reduction) adjusted for macroaggregated albumin (MAA) shunted to the lung.
  • RESULTS: Twenty-one patients underwent twenty-five treatments with SIR microsphere therapy for primary and metastatic liver tumors.
  • CONCLUSIONS: The application of SIR microspheres has been utilized for a variety of liver tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiotherapy. Female. Hepatic Artery / radiation effects. Humans. Male. Microspheres. Middle Aged. Neoplasm, Residual / radiotherapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiotherapy. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259948.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


48. Vrettou E, Hytiroglou P, Sikas N, Soultoyannis I, Goodman ZD: Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives. Virchows Arch; 2005 May;446(5):560-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of primary hepatic carcinoma is reported, which occurred in a 24-year-old woman with a 10-year history of oral contraceptive use, and demonstrated unique morphologic and immunohistochemical features.
  • [MeSH-major] Adenocarcinoma / diagnosis. Contraceptives, Oral, Combined / administration & dosage. Inhibins / analysis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Abdominal Pain. Adult. CA-19-9 Antigen / analysis. Carcinoembryonic Antigen / analysis. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. Magnetic Resonance Imaging. Nausea. Tomography, X-Ray Computed. Vomiting

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Jul;11(7):656-64 [9688187.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2112-6 [3567872.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):516-24 [9647588.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):144-50 [10202672.001]
  • [Cites] Mod Pathol. 1998 Dec;11(12):1160-4 [9872645.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):229-34 [9930145.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):591-7 [12808065.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1387-93 [11391527.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2051-5 [1717133.001]
  • (PMID = 15815932.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Contraceptives, Oral, Combined; 0 / KRT7 protein, human; 0 / Keratin-7; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


49. Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V: Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol; 2010;5:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients.
  • This study was performed to determine the ability of a probiotic containing live lactobacillus acidophilus plus bifidobacterium bifidum to reduce the incidence of radiation-induced diarrhea in locally advanced cervical cancer patients.
  • The primary endpoint was to reduce the incidence of diarrhea, defined by a CTC grade 2 or more, and the need for anti-diarrheal medication.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Double-Blind Method. Female. Humans. Incidence. Middle Aged. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Placebos. Probiotics / therapeutic use. Prospective Studies. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Treatment Outcome. Young Adult


50. Coviello E, Caputi G, Martinelli D, Germinario CA, Prato R: Mortality trends for primary liver cancer in Puglia, Italy. Eur J Cancer Prev; 2010 Nov;19(6):417-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality trends for primary liver cancer in Puglia, Italy.
  • In the region of Puglia, Italy, the mortality rates from primary liver cancer (PLC) show a considerable geographical variability.
  • [MeSH-major] Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cities. Cohort Studies. Humans. Italy / epidemiology. Middle Aged. Mortality / trends. Risk Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647933.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Harzke AJ, Baillargeon JG, Goodman KJ, Pruitt SL: Liver cancer mortality among male prison inmates in Texas, 1992-2003. Prev Med; 2009 Jun;48(6):588-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver cancer mortality among male prison inmates in Texas, 1992-2003.
  • OBJECTIVES: Prevalence estimates for several liver cancer risk factors-hepatitis C, hepatitis B, and history of alcohol abuse-are substantially higher in U.S. prison populations than in the general population.
  • However, liver cancer mortality data from these populations are lacking.
  • The primary aims of this study were to examine trends in liver cancer mortality rates from 1992 to 2003 among male prisoners in the Texas Department of Criminal Justice (TDCJ) and to compare these rates to general population rates.
  • Crude average annual liver cancer death rates, average annual percent changes, and standardized mortality ratios were estimated.
  • RESULTS: Crude liver cancer death rates increased by an average annual 6.1% among male prisoners, which was considerably higher than the average annual percent change among similarly aged males in Texas (2.0%) and the U.S. (2.9%).
  • The number of liver cancer deaths among male prisoners was 4.7 (4.0-5.6) and 6.3 (5.3-7.5) times higher than the expected number of deaths estimated using age-specific rates from these reference populations.
  • CONCLUSIONS: From 1992 to 2003, liver cancer death rates and rate increases were elevated among Texas male prisoners.
  • Findings support previous recommendations for targeted prevention, screening, and treatment of liver cancer risk factors in prison populations.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):556-62 [10451460.001]
  • [Cites] Alcohol Alcohol. 1995 Mar;30(2):177-86 [7662036.001]
  • [Cites] Am J Epidemiol. 1990 Feb;131(2):373-5 [2296988.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 Aug 6;53(30):681-3 [15295312.001]
  • [Cites] JAMA. 2004 Jul 28;292(4):423-4 [15280325.001]
  • [Cites] Am J Public Health. 2004 Jul;94(7):1218-23 [15226146.001]
  • [Cites] Drug Alcohol Depend. 2004 Jun 11;74(3):223-34 [15194200.001]
  • [Cites] J Urban Health. 2004 Mar;81(1):25-37 [15047781.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] JAMA. 2003 Jul 9;290(2):228-37 [12851278.001]
  • [Cites] Public Health. 2003 Jan;117(1):43-8 [12802904.001]
  • [Cites] JAMA. 2003 Jun 4;289(21):2849-56 [12783916.001]
  • [Cites] MMWR Recomm Rep. 2003 Jan 24;52(RR-1):1-36; quiz CE1-4 [12562146.001]
  • [Cites] Vaccine. 2002 Dec 13;21(3-4):312-21 [12450707.001]
  • [Cites] AIDS. 2002 Nov 8;16(16):2236-8 [12409752.001]
  • [Cites] Arch Intern Med. 2000 Nov 27;160(21):3227-30 [11088082.001]
  • [Cites] Public Health Rep. 2009 Jan-Feb;124(1):120-6 [19413034.001]
  • [Cites] Am J Public Health. 2000 Jan;90(1):139-40 [10630155.001]
  • [Cites] Am J Public Health. 2008 Dec;98(12):2278-84 [18923131.001]
  • [Cites] Hepatology. 2008 Nov;48(5):1387-95 [18924228.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203 [16775181.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):762-9 [16702592.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] Addiction. 2006 Feb;101(2):181-91 [16445547.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2197-204 [16206295.001]
  • (PMID = 19289141.001).
  • [ISSN] 1096-0260
  • [Journal-full-title] Preventive medicine
  • [ISO-abbreviation] Prev Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057712-14; United States / NCI NIH HHS / CA / R25 CA057712; United States / NCI NIH HHS / CA / R25 CA 57712; United States / NCI NIH HHS / CA / R25 CA057712-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS190514; NLM/ PMC2879635
  •  go-up   go-down


52. Liu J, Xie Y, Ducharme DM, Shen J, Diwan BA, Merrick BA, Grissom SF, Tucker CJ, Paules RS, Tennant R, Waalkes MP: Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure. Environ Health Perspect; 2006 Mar;114(3):404-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure.
  • Our previous work has shown that exposure to inorganic arsenic in utero produces hepatocellular carcinoma (HCC) in adult male mice.
  • The incidence of HCC in adult male offspring was increased 4-fold and tumor multiplicity 3-fold after transplacental arsenic exposure.
  • Samples of normal liver and liver tumors were taken at autopsy for genomic analysis.
  • Arsenic exposure in utero resulted in significant alterations (p < 0.001) in the expression of 2,010 genes in arsenic-exposed liver samples and in the expression of 2,540 genes in arsenic-induced HCC.
  • Ingenuity Pathway Analysis revealed that significant alterations in gene expression occurred in a number of biological networks, and Myc plays a critical role in one of the primary networks.
  • Liver feminization was evidenced by increased expression of estrogen-linked genes and altered expression of genes that encode gender-related metabolic enzymes.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Carcinog. 2001 Feb;30(2):79-87 [11241755.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 15;206(3):288-98 [16039940.001]
  • [Cites] Toxicol Sci. 2001 Jun;61(2):314-20 [11353140.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1339-45 [11396210.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Apr 15;164(2):161-70 [10764629.001]
  • [Cites] Toxicol Sci. 2000 Jun;55(2):460-7 [10828279.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Environ Health Perspect. 2000 Jul;108(7):655-61 [10903620.001]
  • [Cites] J Toxicol Clin Toxicol. 2000;38(4):395-405 [10930056.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):185-92 [11134558.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5389-95 [11454681.001]
  • [Cites] Mol Pharmacol. 2001 Aug;60(2):302-9 [11455017.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Sep 15;175(3):260-8 [11559025.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64-71 [11578149.001]
  • [Cites] Environ Health Perspect. 2002 Feb;110(2):119-22 [11836136.001]
  • [Cites] Toxicol Lett. 2002 Mar 10;128(1-3):73-84 [11869819.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):777-85 [12016150.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):629-34 [12115494.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1387-97 [12151359.001]
  • [Cites] Alcohol. 2002 Jul;27(3):155-62 [12163143.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:883-6 [12426152.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):757-70 [12727805.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):234-45 [14567983.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):685-93 [14710347.001]
  • [Cites] Toxicol Pathol. 2004 Jan-Feb;32(1):64-72 [14713550.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Am J Public Health. 2004 May;94(5):741-4 [15117692.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32700-8 [15161912.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Lab Invest. 2004 Sep;84(9):1137-47 [15220935.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(12):1255-63 [15345372.001]
  • [Cites] J Toxicol Environ Health A. 2004 Oct 8;67(19):1491-500 [15371225.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] J Hyg Epidemiol Microbiol Immunol. 1988;32(2):137-46 [2457611.001]
  • [Cites] J Pharmacol Exp Ther. 1996 May;277(2):1026-33 [8627513.001]
  • [Cites] J Gastroenterol Hepatol. 1997 Oct;12(9-10):S294-308 [9407350.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4499-508 [9671459.001]
  • [Cites] Toxicol Sci. 1998 Aug;44(2):185-90 [9742656.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1775-85 [9846968.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3414-8 [15526358.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):369-77 [15645121.001]
  • [Cites] FEBS J. 2005 Jan;272(2):413-21 [15654879.001]
  • [Cites] Oncogene. 2005 Mar 10;24(11):1831-46 [15674350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9 [15937110.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61 [11312654.001]
  • (PMID = 16507464.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] N712M78A8G / Arsenic
  • [Other-IDs] NLM/ PMC1392235
  •  go-up   go-down


53. Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA: Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine; 2010 Aug 02;28(34):5597-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoints were quantitative HBsAb titers and adverse events.
  • [MeSH-minor] Adult. Antibody Formation. Female. Hepatitis B / immunology. Hepatitis B / prevention & control. Hepatitis B Antibodies / blood. Humans. Male. Middle Aged. Pilot Projects

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Viral Hepat. 1999 Sep;6(5):405-9 [10607257.001]
  • [Cites] Vaccine. 2010 Feb 10;28(6):1447-50 [19995540.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):492-7 [11170959.001]
  • [Cites] Ren Fail. 2001 Sep;23(5):629-36 [11725909.001]
  • [Cites] Vaccine. 2002 May 31;20 Suppl 3:S18-23 [12184360.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1921-6 [12493258.001]
  • [Cites] Vaccine. 2003 Nov 7;21(31):4545-9 [14575766.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6337-43 [15342423.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4 Suppl 1:S22-8 [1848618.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):929-40 [2033429.001]
  • [Cites] J Clin Gastroenterol. 1992 Jan;14(1):27-30 [1532609.001]
  • [Cites] AIDS. 1992 May;6(5):509-10 [1535502.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):298-306 [8420448.001]
  • [Cites] AIDS. 1994 Apr;8(4):558-9 [7912087.001]
  • [Cites] J Viral Hepat. 1996 May;3(3):149-53 [8871874.001]
  • [Cites] Am J Med. 1997 Sep;103(3):217-22 [9316554.001]
  • [Cites] Cancer J Sci Am. 1997 Sep-Oct;3(5):278-83 [9327151.001]
  • [Cites] Curr Opin Hematol. 1995 May;2(3):227-33 [9372000.001]
  • [Cites] Vaccine. 1998 Dec;16(20):1933-5 [9796046.001]
  • [Cites] Clin Microbiol Rev. 1999 Apr;12(2):351-66 [10194463.001]
  • [Cites] AIDS. 1999 Apr 16;13(6):633-43 [10397557.001]
  • [Cites] Vaccine. 2005 Apr 22;23(22):2902-8 [15780739.001]
  • [Cites] Clin Infect Dis. 2005 Oct 1;41(7):1045-8 [16142673.001]
  • [Cites] Liver Transpl. 2005 Oct;11(10):1228-34 [16184571.001]
  • [Cites] AIDS. 2005 Dec 2;19(18):2117-25 [16284461.001]
  • [Cites] J Hepatol. 2006;44(1 Suppl):S6-9 [16352363.001]
  • [Cites] Vaccine. 2007 Jan 8;25(4):709-18 [16963165.001]
  • [Cites] HIV Med. 2008 Feb;9(2):82-8 [18257771.001]
  • [Cites] AIDS. 2008 Jul 31;22(12):1399-410 [18614862.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Vaccine. 2009 Jul 23;27(34):4731-8 [19540026.001]
  • [Cites] Clin Infect Dis. 2009 Sep 1;49(5):651-81 [19640227.001]
  • [Cites] Clin Infect Dis. 2009 Sep 15;49(6):817-40 [19659433.001]
  • [Cites] Clin Nephrol. 2000 Aug;54(2):138-42 [10968690.001]
  • (PMID = 20600512.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069502; United States / NIAID NIH HHS / AI / U01 AI069513; United States / NIAID NIH HHS / AI / UM1 AI069501; United States / NIAID NIH HHS / AI / U01 AI069474; United States / NIAID NIH HHS / AI / UM1 AI069513; United States / NIAID NIH HHS / AI / U01 AI068636-01; United States / NIAID NIH HHS / AI / U01 AI069434; United States / NIAID NIH HHS / AI / U01 AI069532-01; United States / NIAID NIH HHS / AI / AI038855; United States / NCRR NIH HHS / RR / RR 024160; United States / NIAID NIH HHS / AI / U01 AI069495-01; United States / NIAID NIH HHS / AI / AI 69434; United States / NIAID NIH HHS / AI / AI 69471; United States / NIAID NIH HHS / AI / AI 69474; United States / NIAID NIH HHS / AI / AI 69495; United States / NIAID NIH HHS / AI / UM1 AI069434; United States / NIAID NIH HHS / AI / AI 69501; United States / NIAID NIH HHS / AI / AI 69513; United States / NIAID NIH HHS / AI / AI069532; United States / NIAID NIH HHS / AI / U01 AI027665-110001; United States / NIAID NIH HHS / AI / UM1 AI069495; United States / NIAID NIH HHS / AI / AI 69511; United States / NIAID NIH HHS / AI / U01 AI069484; United States / NIAID NIH HHS / AI / UM1 AI069471; United States / NIAID NIH HHS / AI / U01 AI038855; United States / NIAID NIH HHS / AI / U01 AI068634-01; United States / NIAID NIH HHS / AI / U01 AI069532; United States / NIAID NIH HHS / AI / UM1 AI069484; United States / NIAID NIH HHS / AI / UM1 AI068634; United States / NIAID NIH HHS / AI / AI027665; United States / NIAID NIH HHS / AI / U01 AI069501; United States / NIAID NIH HHS / AI / AI069495; United States / NIAID NIH HHS / AI / U01 AI038855-04; United States / NIAID NIH HHS / AI / AI 69484-02; United States / NIAID NIH HHS / AI / U01 AI068636; United States / NIAID NIH HHS / AI / UM1 AI069474; United States / NCRR NIH HHS / RR / UL1 RR024160; United States / NIAID NIH HHS / AI / U01 AI069495; United States / NIAID NIH HHS / AI / AI 68634; United States / NIAID NIH HHS / AI / U01 AI069511; United States / NIAID NIH HHS / AI / UM1 AI069532; United States / NIAID NIH HHS / AI / AI 69532; United States / NIAID NIH HHS / AI / AI 68636; United States / NIAID NIH HHS / AI / AI068634; United States / NIAID NIH HHS / AI / UM1 AI069511; United States / NIAID NIH HHS / AI / U01 AI027665; United States / NIAID NIH HHS / AI / U01 AI069471; United States / NIAID NIH HHS / AI / U01 AI068634; United States / NIAID NIH HHS / AI / UM1 AI068636
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Hepatitis B Antibodies; 0 / Hepatitis B Vaccines; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS222340; NLM/ PMC2943846
  •  go-up   go-down


54. D'Arrigo A, Belluco C, Ambrosi A, Digito M, Esposito G, Bertola A, Fabris M, Nofrate V, Mammano E, Leon A, Nitti D, Lise M: Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer; 2005 Jun 10;115(2):256-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma.
  • Metastatic spread to the liver is the major contributor to mortality in patients with colorectal carcinoma (CRC).
  • In order to seek for gene expression patterns associated with metastatic potential in primary CRC, we compared the transcriptional profiles of 10 radically resected primary CRCs from patients who did not develop distant metastases within a 5-year follow-up period with those of 10 primary/metastatic tumor pairs from patients with synchronous liver metastases.
  • While a striking transcriptional similarity was observed between the primary tumors and their distant metastases, the nonmetastasizing primary tumors were clearly distinct from the primary/metastatic tumor pairs.
  • Of 37 gene expression differences found between the 2 groups of primary tumors, 29 also distinguished nonmetastasizing tumors from metastases.
  • The gene encoding for mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetyl-glucosaminyl-transferase (GnT-IV) became significantly upregulated in primary/metastatic tumor pairs (p < 0.001).
  • These data support the existence of a specific transcriptional signature distinguishing primary colon adenocarcinomas with different metastatic potential, the further pursuit of which may lead to relevant clinical and therapeutic applications.
  • [MeSH-minor] Adult. Aged. Female. Humans. Lasers. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15688387.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.145 / alpha-1,3-mannosylglycoprotein beta-1,4-N-acetylglucosaminyltransferase
  •  go-up   go-down


55. Wolf JM, Rybicki LA, Lashner BA: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther; 2005 Nov 1;22(9):783-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
  • BACKGROUND: Colorectal cancer in primary sclerosing cholangitis patients with ulcerative colitis is mostly right-sided where concentrations of carcinogenic secondary bile acids are highest.
  • AIM: To investigate whether ursodeoxycholic acid could be chemopreventive for colorectal cancer.
  • METHODS: A historical cohort study was performed on primary sclerosing cholangitis patients with ulcerative colitis where the 28 patients (cases) who were treated with ursodeoxycholic acid for at least 6 months (mean 3.4 +/- 2.7 years) were compared with the 92 patients (controls) who were not treated with ursodeoxycholic acid.
  • The primary outcomes were colorectal cancer and dysplasia.
  • RESULTS: The cumulative incidence of dysplasia or cancer was not significantly different between cases and controls (P = 0.17 by log-rank test).
  • The adjusted relative risk for cases of developing dysplasia or cancer was 0.59 (95% CI 0.26-1.36).
  • CONCLUSION: In ulcerative colitis patients with primary sclerosing cholangitis, ursodeoxycholic acid did not reduce the risk of developing cancer or dysplasia.
  • [MeSH-minor] Adult. Age Factors. Age of Onset. Cohort Studies. Colon / pathology. Female. Humans. Liver Transplantation. Male. Rectum / pathology. Risk Factors. Sex Factors


56. Onken MD, Worley LA, Harbour JW: Association between gene expression profile, proliferation and metastasis in uveal melanoma. Curr Eye Res; 2010 Sep;35(9):857-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The study included 28 primary uveal melanomas with extensive clinical, pathologic, and genetic annotation, including age, gender, ciliary body involvement, tumor basal diameter, thickness, cell type, gene expression profile, status of chromosomes 3 and 8p, aneuploidy, and clinical outcome.

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Eye Res. 2006 Jan;31(1):57-67 [16421020.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):748-9 [16226537.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1466-71 [17332290.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):115-22 [18172260.001]
  • [Cites] Melanoma Res. 2008 Jun;18(3):191-200 [18477893.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3737-45 [18559591.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):153-66 [19238148.001]
  • [Cites] Ophthalmology. 2001 Feb;108(2):367-71 [11158814.001]
  • [Cites] Curr Eye Res. 2002 Feb;24(2):105-8 [12187481.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7205-9 [15492234.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] Ophthalmology. 1990 Oct;97(10):1275-80 [2243677.001]
  • [Cites] Curr Eye Res. 1991 May;10(5):479-84 [1889233.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):357-62 [8664054.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4602-9 [16651410.001]
  • (PMID = 20795869.001).
  • [ISSN] 1460-2202
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY002687; United States / NCI NIH HHS / CA / R01 CA125970; United States / NCI NIH HHS / CA / R01 CA125970-04; United States / NEI NIH HHS / EY / P30 EY02687C
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS337043; NLM/ PMC3230327
  •  go-up   go-down


57. Bruzoni M, Parikh P, Celis R, Are C, Ly QP, Meza JL, Sasson AR: Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review. Am J Surg; 2009 Mar;197(3):376-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review.
  • There is a lack of information on the management of the primary tumor in patients who present with unresectable synchronous hepatic metastases.
  • Patients were divided into 3 groups: PNFNET without evidence of hepatic metastasis (group A), PNFNET with metastatic disease involving less than 50% of the liver (group B), and PNFNET with metastatic disease involving more than 50% of the liver (group C).
  • CONCLUSIONS: In selected patients, resection of the primary pancreatic tumor even in the setting of unresectable but limited hepatic metastases may be indicated.
  • [MeSH-major] Liver Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Neuroendocrine Tumors / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies


58. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL, Hsu HC: Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle; 2006 Nov;5(22):2676-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • L2DTL gene expression increased during G1/S phase, and the DNA synthesis in liver regeneration.
  • L2DTL downregulation by RNAi oligos led to reduced cancer cell growth and invasion capability in vitro, in which microarray analysis disclosed dysregulation of genes involved in cell cycle regulation, chromosome segregation, and cell division.
  • L2DTL overexpressed in 59% of 270 resected, unifocal, primary HCCs.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Carcinoma, Hepatocellular / metabolism. Cell Cycle. Centrosome / metabolism. Liver Neoplasms / metabolism. Nuclear Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cadherins / metabolism. Down-Regulation. HeLa Cells. Humans. Middle Aged. RNA, Messenger / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Ubiquitin-Protein Ligases


59. Yan K, Wang YB, Chen MH, Gao W, Yang W, Dai Y, Yin SS: [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors]. Zhonghua Yi Xue Za Zhi; 2005 Aug 31;85(33):2322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors].
  • OBJECTIVE: To investigate the prognostic factors affecting outcome in Radiofrequency (RF) ablation of primary hepatic tumors by univariate and multivariate analyses, and to assess the therapeutic efficacy of Radio-frequency ablation.
  • METHODS: A total of 172 patients with primary hepatic tumors underwent RF treatment in our department between 1999 and 2004.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321224.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


60. Umeda T, Abe H, Kurumi Y, Naka S, Shiomi H, Hanasawa K, Morikawa S, Tani T: Magnetic resonance-guided percutaneous microwave coagulation therapy for liver metastases of breast cancer in a case. Breast Cancer; 2005;12(4):317-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance-guided percutaneous microwave coagulation therapy for liver metastases of breast cancer in a case.
  • Real-time magnetic resonance (MR) imaging enables the application of percutaneous microwave coagulation for high-risk patients with metastatic liver tumours.
  • MR-guided percutaneous microwave coagulation therapy is effective for treatment of not only primary liver tumours but also metastatic breast cancers in the liver, which are not diffuse but discrete, and difficult to treat with only chemo-and endocrine therapy.
  • We report a 44-year-old Japanese woman who underwent modified radical mastectomy for right breast cancer (T1c N0 M0 Stage I).
  • Three years after the operation, she developed two metastatic liver tumours and was treated by MR-guided percutaneous microwave coagulation, achieving a complete response (CR) without any recurrence for 15 months as of the present.
  • Additional clinical trials will be valuable to delineate the effectiveness and safety of MR-guided percutaneous microwave coagulation therapy for controlling the liver metastases of breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Electrocoagulation / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Microwaves / therapeutic use
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Mastectomy, Modified Radical. Treatment Outcome


61. Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O'Toole D, Mitry E, Hentic O, Hammel P, Lévy P, Ravaud P, Rougier P, Ruszniewski P: Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer; 2007 Jan 15;96(1):49-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours.
  • Transcatheter arterial chemoembolisation (TACE) has been reported to be an efficient treatment of liver metastases of endocrine tumours in short series of patients.
  • The aim of this work is to identify predictors of response to TACE for liver metastases of endocrine tumours.
  • Primary tumour was located in the pancreas for 19 patients, and had been removed in 43.
  • This large study confirms the previously reported results of TACE regarding its efficacy for the treatment of liver metastases of endocrine tumours.
  • [MeSH-major] Body Mass Index. Chemoembolization, Therapeutic / methods. Endocrine Gland Neoplasms / therapy. Liver Neoplasms / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Streptozocin / adverse effects. Streptozocin / therapeutic use. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] Pancreatology. 2006;6(1-2):77-85 [16327283.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Feb;12(2):151-7 [10741928.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):136-40 [12541121.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):484-95 [12879464.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):261-7 [12967136.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2435-9 [14638345.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] Digestion. 2003;68(2-3):94-101 [14593235.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):439-45 [14691120.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):446-53 [14691122.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):515-20 [14962717.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):648-57 [14966087.001]
  • [Cites] Br J Nutr. 2004 Sep;92(3):347-55 [15469638.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:74-8 [15477722.001]
  • [Cites] Prog Surg. 1974;13:141-66 [4614326.001]
  • [Cites] N Engl J Med. 1980 Nov 20;303(21):1189-94 [6252466.001]
  • [Cites] Bull Cancer. 1989;76(9):1029-37 [2695182.001]
  • [Cites] Tumour Biol. 1992;13(1-2):27-35 [1317054.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2624-30 [8384072.001]
  • [Cites] Radiology. 1993 Nov;189(2):541-7 [7692465.001]
  • [Cites] Am J Surg. 1995 May;169(5):523-8 [7747834.001]
  • [Cites] Radiology. 1996 Jan;198(1):33-40 [8539401.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):286-93 [9495200.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1751-6 [15532819.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2434-5; author reply 2435 [15800342.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1668-84 [15887158.001]
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 17164755.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5W494URQ81 / Streptozocin; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2360220
  •  go-up   go-down


62. Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P: Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol; 2008 Feb;13(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
  • BACKGROUND: Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease.
  • METHODS: In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Liver Neoplasms / drug therapy. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein Kinases / metabolism. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):649-53 [14991931.001]
  • [Cites] Liver Transpl. 2004 Oct;10(10):1301-11 [15376305.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1843-52 [16767220.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):986-91 [9744316.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1392-3 [12176410.001]
  • [Cites] Radiology. 2004 Jan;230(1):300-1; author reply 301-2 [14695404.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1420-5 [15770715.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):226-30 [9705862.001]
  • [Cites] Transpl Int. 2005 Jan;18(1):89-94 [15612989.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Liver Transpl. 2001 Jun;7(6):473-84 [11443573.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4442-5 [15483011.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):789-93 [15868910.001]
  • [Cites] Acta Oncol. 2005;44(5):496 [16118084.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3818-22 [16799623.001]
  • (PMID = 18307022.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


63. Kanai M, Morita S, Matsumoto S, Nishimura T, Hatano E, Yazumi S, Sasaki T, Yasuda H, Kitano T, Misawa A, Ishiguro H, Yanagihara K, Ikai I, Doi R, Fukushima M: A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Ann Oncol; 2009 Aug;20(8):1397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Data on smoking history and incidence of grade 3-4 neutropenia were retrospectively gathered for 103 chemo-naive patients treated with gemcitabine monotherapy (59 patients with pancreatic, 41 with hepatobiliary and three with other cancers).
  • After adjustment for age, gender, platelet and baseline neutrophil counts, history of surgery for primary cancer, creatinine concentration, hemoglobin concentration, aspartate aminotransferase concentration, alanine aminotransferase concentration and total bilirubin concentration, logistic regression analysis identified a history of smoking as an independent inverse predictor of gemcitabine-induced neutropenia (OR 0.188, 95% CI 0.057-0.618; P = 0.006).

  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457938.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


64. Trivedi P, Gupta A, Pasricha S, Agrawal G, Shah M: Isolated skull base metastasis as the first manifestation of hepatocellular carcinoma--a rare case report with review of literature. J Gastrointest Cancer; 2009;40(1-2):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequent examination revealed a large mass involving superior segment of right lobe of liver, which was confirmed as hepatocellular carcinoma on histopathological examination.
  • We report here an unusual case of solitary skull base metastasis from hepatocellular carcinoma prior to the diagnosis of primary tumor.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Korean J Gastroenterol. 2008 Dec;52(6):389-93 [19096257.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 Dec;44(12):1171-2 [6278095.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Mar;32(3):166-8 [1377801.001]
  • [Cites] Hong Kong Med J. 2002 Feb;8(1):48-51 [11861994.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Dec;33(12):839-44 [7512232.001]
  • [Cites] Radiology. 1986 Jul;160(1):175-8 [3012630.001]
  • [Cites] Taiwan Yi Xue Hui Za Zhi. 1979 Jun;78(6):594-604 [226652.001]
  • [Cites] Surg Neurol. 1985 Jan;23(1):41-8 [2981120.001]
  • [Cites] Bull Soc Med Afr Noire Lang Fr. 1968;13(3):577-85 [4306564.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] J Gastroenterol Hepatol. 1995 Jul-Aug;10 (4):413-8 [8527707.001]
  • [Cites] Skull Base Surg. 2000;10(2):81-6 [17171106.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Sep;13(9):1083-8 [11564960.001]
  • [Cites] HNO. 2001 Feb;49(2):126-9 [11270194.001]
  • [Cites] Neurol Med Chir (Tokyo). 1985 Mar;25(3):229-34 [2409470.001]
  • [Cites] World J Gastroenterol. 2006 Nov 7;12(41):6727-9 [17075993.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):63-9 [16215817.001]
  • [Cites] Neurosurgery. 1990 May;26(5):863-6 [2162018.001]
  • [Cites] Eur J Neurol. 2007 Apr;14(4):408-12 [17388989.001]
  • [Cites] J Surg Oncol. 1988 Sep;39(1):33-4 [2843717.001]
  • [Cites] Acta Neurochir (Wien). 2007 Feb;149(2):185-90 [17180305.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1037-9 [1335033.001]
  • (PMID = 19705301.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


65. Granci V, Bibeau F, Kramar A, Boissière-Michot F, Thézénas S, Thirion A, Gongora C, Martineau P, Del Rio M, Ychou M: Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer; 2008 Oct;44(15):2312-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analysed TRAIL-R 1, -2, -3 and -4 expression by immuno-histochemistry in CRC, using tissue micro arrays, and found that concomitant low/medium TRAIL-R1 and high TRAIL-R3 expression in primary CRC is significantly associated with a poor response to 5-FU-based first-line chemotherapy and with shorter progression-free survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Disease Progression. Disease-Free Survival. Female. Fluorouracil / therapeutic use. GPI-Linked Proteins. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Proteins / metabolism. Prognosis. Treatment Outcome. Tumor Necrosis Factor Decoy Receptors / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755584.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10C protein, human; 0 / Tumor Necrosis Factor Decoy Receptors; U3P01618RT / Fluorouracil
  •  go-up   go-down


66. Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Monden M: Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg; 2006 Jul-Aug;10(7):987-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In conclusion, the preoperative diagnosis is difficult; liver masses similar to those of HCC, together with moderately elevated serum AFP and CA19-9 levels, are reliable indicators of cHCC-CC.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Oct 15;78(8):1671-6 [8859179.001]
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [Cites] Radiology. 2004 Jan;230(1):135-41 [14631050.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] Hepatology. 1993 Nov;18(5):1090-5 [7693572.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):832-4 [10919041.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1487-90 [12397714.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Surg Oncol. 2001 Jan;76(1):37-46 [11223823.001]
  • [Cites] Surg Today. 2002;32(8):742-6 [12181730.001]
  • [Cites] Ann Surg. 1990 Mar;211(3):277-87 [2155591.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):751-8 [11477591.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):956-64 [7545644.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):989-97 [12170085.001]
  • (PMID = 16843869.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, Flentje M: Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol; 2006;45(7):838-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy of primary liver cancer and hepatic metastases.
  • The purpose was to evaluate the clinical results of stereotactic radiotherapy in primary liver tumors and hepatic metastases.
  • Five patients with primary liver cancer and 39 patients with 51 hepatic metastases were treated by stereotactic radiotherapy since 1997.
  • Median follow-up was 15 months (2-48 months) for primary liver cancer and 15 months (2-85 months) for hepatic metastases.
  • While all primary liver cancers were controlled, nine local failures (3-19 months) of 51 metastases were observed resulting in an actuarial local control rate of 92% after 12 months and 66% after 24 months and later.
  • Stereotactic irradiation of primary liver cancer and hepatic metastases offers a locally effective treatment without significant complications in patients, who are not amenable for surgery.
  • [MeSH-major] Carcinoma / secondary. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Radiotherapy Dosage. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982548.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


68. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL: Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer; 2007 Sep 1;110(5):1059-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers.
  • The primary objective of this study was to determine the proportion of hepatocellular carcinoma (HCC) patients treated with erlotinib who were alive and progression-free (PFS) at 16 weeks of continuous treatment.
  • Tumor response was assessed every 2 cycles by using Response Evaluation Criteria in Solid Tumors (RECIST; National Cancer Institute Cancer Therapy Evaluation Program, Bethesda, Md) criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diarrhea / virology. Drug Administration Schedule. Erlotinib Hydrochloride. Exanthema / chemically induced. Fatigue / chemically induced. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17623837.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01 CM17003
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


69. Nagashima I, Takada T, Adachi M, Nagawa H, Muto T, Okinaga K: Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol; 2006 Oct 21;12(39):6305-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors.
  • AIM: To select accurately good candidates of hepatic resection for colorectal liver metastasis.
  • Using selected variables, we created a scoring formula to classify patients with colorectal liver metastases to select good candidates for hepatic resection.
  • In addition, these three factors: serosa invasion, local lymph node metastases of primary cancers, and post-operative disease free interval less than 1 year including synchronous hepatic metastasis, were not significant, however, they were selected by a stepwise method of Cox regression analysis (0.05 < P < 0.20).
  • Using these six variables, we created a new scoring formula to classify patients with colorectal liver metastases.
  • CONCLUSION: Both, our new scoring system and the positive number of significant prognostic factors are useful to classify patients with colorectal liver metastases in the preoperative selection of good candidates for hepatic resection.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Patient Selection. Severity of Illness Index
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):59-66 [10636103.001]
  • [Cites] Int Surg. 1993 Jan-Mar;78(1):16-9 [8473076.001]
  • [Cites] Surgery. 2001 Apr;129(4):408-13 [11283530.001]
  • [Cites] Surgery. 1988 Mar;103(3):278-88 [3278402.001]
  • [Cites] Ann Surg. 1989 Aug;210(2):127-38 [2667471.001]
  • [Cites] Ann Surg. 1991 Aug;214(2):107-13 [1867517.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):797-801 [1873704.001]
  • [Cites] Arch Surg. 1992 May;127(5):561-8; discussion 568-9 [1575626.001]
  • [Cites] Lancet. 1992 Aug 29;340(8818):502-6 [1354275.001]
  • [Cites] Cancer. 1993 Jun 15;71(12 Suppl):4252-66 [8508388.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1032-5 [8402060.001]
  • [Cites] Am J Surg. 1993 Dec;166(6):743-6; discussion 746-8 [8273861.001]
  • [Cites] Surgery. 1994 Oct;116(4):703-10; discussion 710-1 [7940169.001]
  • [Cites] Dis Colon Rectum. 1994 Nov;37(11):1078-82 [7956573.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1077-80 [9278644.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1081-4 [9278645.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):566-71 [9563547.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):706-12 [9869517.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):739-43 [10086660.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(1):16-22 [10436233.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • (PMID = 17072953.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088138
  •  go-up   go-down


70. Messick CA, Sanchez J, Dejulius KL, Church JM, Kalady MF: Genetic and molecular diversity of colon cancer hepatic metastases. Surgery; 2009 Aug;146(2):227-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and molecular diversity of colon cancer hepatic metastases.
  • BACKGROUND: Colon cancer arises through distinct molecular pathways resulting in diverse tumor populations demonstrated by differences in microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and mutations in oncogenes KRAS and BRAF.
  • Although these molecular differences are well-described for primary neoplasms, the molecular nature of hepatic metastases is not well-characterized.
  • This study seeks to describe molecular characteristics of colon cancer hepatic metastases in terms of oncogenic pathway.
  • METHODS: Tumor DNA was isolated from fresh frozen hepatic metastases from colon cancer and analyzed for MSI by polymerase chain reaction (PCR)-based microsatellite analysis and for CIMP using MethyLight quantitative PCR.
  • Unfortunately, tissue from the primary neoplasms from these patients were not available RESULTS: Thirty patients with liver metastases from colon cancer were studied.
  • Literature describing primary colon cancers reports an incidence of approximately 20% MSI-H, 20% CIMP-positive, 35% KRAS mutants, and 17% BRAF mutants.
  • CONCLUSION: Hepatic metastases from colon cancer, like primary colon adenocarcinomas, show genetic and molecular diversity.
  • Furthermore, hepatic metastases may have a different incidence of MSI and methylation compared with primary neoplasms.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / genetics. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. CpG Islands / genetics. Female. Genes, ras / genetics. Humans. Male. Microsatellite Instability. Middle Aged. Mutation. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628078.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


71. Schiel KA: An etiologic model proposing that sporadic adult-onset carcinoma is extramedullary hematopoiesis. Med Hypotheses; 2006;67(1):93-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An etiologic model proposing that sporadic adult-onset carcinoma is extramedullary hematopoiesis.
  • This model proposes that primary carcinomatous tumors and almost all metastases are extramedullary hematopoietic tissue formed to compensate for reduced hematopoietic activity in the bone marrow.
  • Specific carcinoma morphologies are equated to stages in endochondral bone and marrow formation and, as such, cancer cell identity varies with morphology.
  • Lobular carcinoma in situ consists of cancer cell clusters separated by narrow clear spaces that, under high magnification, appear vascular.
  • If cancer cells are not the enemy, but desperately needed immature blood cells, and the medical problem is not the presence of tumors, but the inefficiency of this extramedullary hematopoietic tissue, then treatment should focus on increasing marrow hematopoiesis.
  • [MeSH-major] Carcinoma / etiology. Hematopoiesis, Extramedullary. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Bone Marrow Cells. Granulocytes / metabolism. Hematopoietic Stem Cells / cytology. Humans. Leukemia / metabolism. Models, Biological. Neoplasm Metastasis. Primary Myelofibrosis / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540257.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


72. Yasumoto T, Murakami T, Katsumoto Y, Hashimoto T, Noda S, Murata K, Kinuta M, Nakamura H: [Radiofrequency ablation for hepatocellular carcinoma and liver metastases]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1596-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiofrequency ablation for hepatocellular carcinoma and liver metastases].
  • The primary lesions of patients with metastatic liver tumors were 9 colon cancer, 2 rectal cancer, 2 breast cancer, 2 gastric cancer, and 1 esophageal cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315881.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


73. Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA: Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer; 2007;7:118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
  • The role of gene polymorphisms of several cytochrome P450 enzymes in digestive cancer risk has been extensively investigated.
  • This study aims to examine associations between common CYP3A4 and CYP3A5 polymorphisms and digestive cancer risk.
  • METHODS: CYP3A4 and CYP3A5 genotypes were determined in 574 individuals including 178 patients with primary liver cancer, 82 patients with gastric cancer, 151 patients with colorectal cancer, and 163 healthy individuals.
  • RESULTS: The variant allele frequencies for patients with liver cancer, gastric cancer, colorectal cancer and healthy controls, respectively, were: CYP3A4*1B, 4.8 % (95% C.I.
  • CONCLUSION: Common polymorphisms on CYP3A4 and CYP3A5 genes do not modify the risk of developing digestive cancers in Western Europe.
  • [MeSH-major] Colorectal Neoplasms / genetics. Cytochrome P-450 Enzyme System / genetics. Genetic Variation. Liver Neoplasms / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Chi-Square Distribution. Cytochrome P-450 CYP3A. Female. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Polymorphism, Genetic. Reference Values. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):519-22 [10769717.001]
  • [Cites] Am J Epidemiol. 2004 Nov 1;160(9):825-41 [15496535.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):209-14 [11181440.001]
  • [Cites] Clin Chem. 2001 Feb;47(2):348-51 [11159790.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jun;16(6):631-5 [11422615.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1259-66 [11751443.001]
  • [Cites] Pharmacogenetics. 2002 Mar;12(2):145-50 [11875368.001]
  • [Cites] Clin Pharmacol Ther. 2002 Mar;71(3):196-204 [11907494.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(5):385-92 [12210502.001]
  • [Cites] Drug Metab Rev. 2002 Aug;34(3):667-76 [12214673.001]
  • [Cites] Br J Cancer. 2002 Sep 9;87(6):681-6 [12237780.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1668-71 [12324482.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1019-24 [12376502.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1839-49 [12419832.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1897-901 [12419838.001]
  • [Cites] Hum Hered. 2002;54(1):13-21 [12446983.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:447-52 [12505350.001]
  • [Cites] Br J Clin Pharmacol. 2003 Jan;55(1):68-76 [12534642.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:149-73 [12171978.001]
  • [Cites] J Pharm Pharmacol. 2003 Jan;55(1):59-66 [12625868.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):527-34 [12813131.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):928-32 [14504207.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):595-606 [14515058.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):607-18 [14515059.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1257-63 [14535982.001]
  • [Cites] Pharmacogenomics. 2004 Apr;5(3):243-72 [15102541.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Clin Pharmacol Ther. 2004 Aug;76(2):99-103 [15289786.001]
  • [Cites] Am J Epidemiol. 2004 Nov 1;160(9):842-52 [15496536.001]
  • [Cites] Hum Genet. 1986 Aug;73(4):320-6 [3017841.001]
  • [Cites] Carcinogenesis. 1991 Feb;12(2):355-9 [1899812.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):101-8 [8261428.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Jul;270(1):414-23 [8035341.001]
  • [Cites] Carcinogenesis. 1994 Dec;15(12):2715-20 [8001226.001]
  • [Cites] Pharmacogenetics. 1994 Oct;4(5):247-59 [7894497.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2167-70 [7554070.001]
  • [Cites] Age Ageing. 1997 Mar;26(2):147-51 [9177672.001]
  • [Cites] Mutat Res. 1997 May 12;376(1-2):153-60 [9202751.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1623-30 [9276639.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1225-9 [9719084.001]
  • [Cites] Environ Health Perspect. 1994 Oct;102(10):852-3 [9644192.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8461-7 [15548719.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):331-5 [15637738.001]
  • [Cites] J Cell Biochem. 2005 Apr 1;94(5):917-43 [15578590.001]
  • [Cites] World J Gastroenterol. 2005 Mar 28;11(12):1867-71 [15793883.001]
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1077-83 [15801491.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):275-82 [15978331.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5552-9 [16110016.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):299-305 [16171783.001]
  • [Cites] BMC Clin Pharmacol. 2005;5:4 [16253141.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):259-64 [15352038.001]
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1087-91 [11099063.001]
  • (PMID = 17605821.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  • [Other-IDs] NLM/ PMC1931602
  •  go-up   go-down


74. Wang ZP, Liu YT, Yang J: [Classification and regression tree analysis of 154 patients with cancer of unknown primary]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):690-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Classification and regression tree analysis of 154 patients with cancer of unknown primary].
  • OBJECTIVE: To explore the prognostic factors and their impact on survival of patients with cancer of unknown primary (CUP).
  • METHODS: The clinical and follow up data of 154 CUP patients referred to the Cancer Hospital & Institute, Chinese Academy of Medical Sciences from January 1, 2003 to December 31, 2007 were analyzed.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Neoplasms, Unknown Primary / classification
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Regression Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122385.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


75. Verslype C, Libbrecht L: The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Pract Res Clin Gastroenterol; 2007;21(6):983-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults.
  • The finding of a focal solid liver lesion represents a challenge for the clinician in terms of the most optimal diagnostic and therapeutic algorithm.
  • Tumours may arise from hepatocytes (hepatocellular adenoma, dysplastic nodules and carcinoma), bile ducts (cholangiocarcinoma) or mesenchymal tissue (hemangioma, epithelioid haemangioendothelioma), or are metastases from primary tumours outside the liver.
  • However, small hypervascular lesions in a cirrhotic liver may be difficult to characterise.
  • The therapy of a focal liver lesion is determined by its natural history and the functional status of the surrounding liver parenchyma.
  • Selected patients with primary liver cancer are candidates for liver transplantation, while patients with advanced malignant tumours have a poor outcome.
  • [MeSH-major] Bile Duct Neoplasms. Liver Cirrhosis / complications. Liver Neoplasms. Precancerous Conditions
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / etiology. Adenoma, Liver Cell / therapy. Adult. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangiocarcinoma / therapy. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / etiology. Focal Nodular Hyperplasia / therapy. Hemangioma / diagnosis. Hemangioma / etiology. Hemangioma / therapy. Humans

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070699.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


76. Gasanov ISh, Polikarpov AA, Tarazov PG, Granov DA, Generalov MI: [Rentgenoendovascular interventions into treatment of patients with unresectable metastases of gastric cancer into the liver]. Vestn Khir Im I I Grek; 2008;167(5):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rentgenoendovascular interventions into treatment of patients with unresectable metastases of gastric cancer into the liver].
  • In the period from 1992 through 2006 transcatheter therapy was carried out in 46 patients with unresectable metastases of gastric cancer (MGC) into the liver.
  • The methods of interventional radiology are thought to be perspective for treatment of unresectable metastases into the liver.
  • [MeSH-major] Adenocarcinoma. Liver Neoplasms. Stomach Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Second Primary. Retrospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069816.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


77. Sapisochin G, Bilbao I, Balsells J, Dopazo C, Caralt M, Lázaro JL, Castells L, Allende H, Charco R: Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg; 2010 Sep;34(9):2146-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series.
  • BACKGROUND: The aim of this study was to ascertain the outcome of liver transplantation (LT) due to hepatocellular carcinoma (HCC) in patients who had undergone previous liver resection (LR) for HCC.
  • METHODS: A case-control study (1:2) was designed to compare patients who underwent LT due to HCC recurrence with a previous LR for HCC (study group) with those who underwent LT for primary HCC but without previous LR (control group).
  • RESULTS: From January 1990 to December 2007, a total of 303 cirrhotic patients with primary HCC were evaluated for surgery.
  • Primary LT was performed in 191 and LR in 100.
  • CONCLUSIONS: Liver transplantation can be safely performed after a previous LR for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Liver Cirrhosis / complications. Liver Function Tests. Male. Middle Aged. Prognosis. Reoperation. Treatment Outcome. Ultrasonography


78. Newman E, Potmesil M, Ryan T, Marcus S, Hiotis S, Yee H, Norwood B, Wendell M, Muggia F, Hochster H: Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Semin Oncol; 2005 Dec;32(6 Suppl 9):S97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A phase II trial, using neoadjuvant chemotherapy and intraperitoneal (IP) consolidation, was conducted in patients with locally advanced, potentially resectable gastric cancer or cancer of the gastroesophageal junction, both staged as T3N0, T4N0, or any TN1 or TN2 disease.
  • Evidence of primary-tumor downstaging was documented in at least one half of the patients.
  • Sites of first recurrences were outside the abdominal cavity in seven patients, in the liver in two, and in the abdominal cavity in four patients.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Esophagectomy. Female. Floxuridine / administration & dosage. Floxuridine / adverse effects. Gastrectomy. Humans. Infusions, Parenteral. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399443.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


79. Vasamiliette J, Hohenberger P, Schoenberg S, Diehl S, Dinter DJ, Marx A, Stroebel P, Strauss LG, Dimitrakopoulou-Strauss A: Treatment monitoring with 18F-FDG PET in metastatic thymoma after 90Y-Dotatoc and selective internal radiation treatment (SIRT). Hell J Nucl Med; 2009 Sep-Dec;12(3):271-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 39 years old male patient with a history of an unresectable thymoma and synchronous liver metastases was referred tor our position.
  • Since the therapeutic response was unsatisfactory, a gallium-68 ((68)Ga)-Dotatoc-positron emission tomography (PET) was performed and demonstrated an enhanced SSTR 2 expression in the primary tumor but not in the liver metastases.
  • Outcome after treatment was monitored by (18)F-FDG-PET and CT and showed a response only of the primary tumor.
  • Selective internal radiation treatment (SIRT) with (90)Y microspheres was then applied for the liver metastases. (18)F-FDG uptake showed that metabolism in the liver metastases decreased after SIRT.
  • MRI of the liver demonstrated a decrease in vascularization and a modest decrease in tumor volume.
  • Therefore, surgical resection of the primary thymoma was initiated.
  • [MeSH-major] Fluorodeoxyglucose F18. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Positron-Emission Tomography / methods. Thymoma / secondary. Thymoma / therapy. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Humans. Male. Prognosis. Radiopharmaceuticals / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936342.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


80. Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, Ahrar K, Wallace MJ, Cohen A, Coldwell DM, Kennedy AS, Hicks ME: Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics; 2005 Oct;25 Suppl 1:S41-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgical resection of primary or metastatic liver cancer, with or without adjuvant chemotherapy, is the most effective method for enhancing survival; however, hepatic malignancies in the vast majority of patients are unresectable both at initial manifestation and at recurrence.
  • Recently, the Food and Drug Administration approved the transarterial administration of yttrium-90 microspheres for liver-directed therapy.
  • [MeSH-major] Drug Carriers. Liver Neoplasms / radiotherapy. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adult. Aged. Equipment Design. Female. Humans. Male. Microspheres. Middle Aged. Radiotherapy / instrumentation. Radiotherapy / methods. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2005.
  • (PMID = 16227496.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Yttrium Radioisotopes
  • [Number-of-references] 48
  •  go-up   go-down


81. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Lück HJ, Kettner E, Hilfrich J, Eiermann W, Torode J, Schneeweiss A: A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat; 2005 Jan;89(2):165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
  • The clinical benefit and safety of the EGFR tyrosine kinase inhibitor gefitinib ('Iressa')1 was evaluated in this Phase II, multicentre study of patients with taxane and anthracycline pretreated, metastatic breast cancer.
  • Primary endpoint was the clinical response rate to the study treatment.
  • RESULTS: One patient (1.7%) had objective partial tumor response of her liver and pleural metastasis.
  • Two patients reported a significant improvement in pain at metastatic sites (1 liver, 1 bone).
  • CONCLUSIONS: Gefitinib monotherapy at 500 mg daily did not appear to be efficacious in the treatment of heavily pretreated metastatic breast cancer patients.
  • [MeSH-minor] Adult. Aged. Anthracyclines / pharmacology. Anthracyclines / therapeutic use. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Survival Analysis. Taxoids / pharmacology. Taxoids / therapeutic use. Treatment Outcome


82. Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS: Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1084-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pelvis (eight cases) was the most common site of recurrence followed by the lung (four cases) and the liver (one case).
  • Surgery is the primary treatment for recurrent endometrial stromal sarcoma when feasible.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179547.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet; 2008 Mar 22;371(9617):1007-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
  • BACKGROUND: Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common.
  • We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.
  • 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group).
  • The primary objective was to detect a hazard ratio (HR) of 0.71 or less for progression-free survival.
  • Primary analysis was by intention to treat.
  • INTERPRETATION: Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Perioperative Care / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Mar;15(3):460-6 [14998849.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):871-83; discussion 883-4 [14631224.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Biometrics. 1976 Sep;32(3):691-4 [963178.001]
  • [Cites] Stat Med. 1990 Dec;9(12):1439-45 [2281231.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):756-62 [9860474.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):663-9 [10442188.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9073-8 [16361615.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):1-7 [16371728.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10):1261-8 [16947009.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1299-300; author reply 1300 [17401028.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1639-41 [17470854.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4906-11 [18794541.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • [CommentIn] Lancet. 2008 Mar 22;371(9617):963-5 [18358910.001]
  • [CommentIn] J Clin Oncol. 2008 Oct 20;26(30):4862-3 [18794535.001]
  • [CommentIn] Lancet. 2008 Jul 19;372(9634):202-3; author report 203 [18640447.001]
  • (PMID = 18358928.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00006479
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-32; United States / NCI NIH HHS / CA / 5U10 CA11488-35; United States / NCI NIH HHS / CA / 5U10-CA11488-28; United States / NCI NIH HHS / CA / 5U10 CA11488-31; United States / NCI NIH HHS / CA / 5U10 CA11488-37; United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10-CA11488-29; United Kingdom / Cancer Research UK / / ; United States / NCI NIH HHS / CA / 5U10 CA11488-36; United States / NCI NIH HHS / CA / 5U10 CA11488-33; United States / NCI NIH HHS / CA / 5U10 CA11488-34; United States / NCI NIH HHS / CA / 5U10 CA11488-30
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2277487
  • [Investigator] Hohenberger W; Iveson T; Karner J; Levi J; Hugh T; De Greve J; Chan A; Davidson B; Lindnér P; Peeters M; Stein B; Diamond T; Ducreux M; Lasser P; Graeven U; Paillot B; Doran J; Gouillat C; Iesalnieks I; Jauch KW; Jagot-Lacoussiere P; Jansen RL; Koehne H; Konopke R; Otto F; Sherlock D; Van Hazel G; Ackland S; Bedenne L; Bories E; Clavero-Fabri MC; Conroy T; Kaminsky-Forrett MC; Husseini F; Karapetis C; Müller L; Price T; Rosenberg R; Schott J; Tschmelitsch J; Van Laethem JL; Wals J; Weimann A; Arnaud JP; Arsene D; Auby D; Bhattacharya S; Cebon E; Cherqui D; Confente C; Dousset B; Frickhofen N; Frilling A; Evan P; Ganju V; Höffken K; Lazorthes F; Letoublon C; Madroszyk A; Nitti D; Orr B; Pariente EA; Pector JC; Raoul JL; Rees M; Ridwelski K; Rouanet P; Toogood GJ; Vergauwe P; Wilke HJ; Kaplan R; Horiot JC; Littbrand B; Awada A; Stenning S; Lejeune F
  •  go-up   go-down


84. Zhang TL, Ma SH, Xiu DR, Song SB, Yuan CH, Jia YM, Gong EC: [The pathological feature of primary hepatic carcinoma on explanted liver and its significance]. Zhonghua Wai Ke Za Zhi; 2010 Jul 1;48(13):964-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The pathological feature of primary hepatic carcinoma on explanted liver and its significance].
  • OBJECTIVE: To investigate the pathological feature of primary hepatic carcinoma and the clinical significance.
  • METHODS: From August 2000 to December 2007, there were 89 patients with cirrhosis and carcinoma of liver who accepted whole liver resection.
  • The whole liver was cut into 10 mm slices to examine the tumor size, number, distribution, capsule, satellite nodes, portal vein tumor thrombi (PVTT).
  • RESULTS: The total of 89 cases included hepatocellular carcinoma in 86 cases and cholangiocarcinoma in 3 cases; 53 cases with multiple tumors and 36 cases with solitary tumor; complete capsule only in 14 cases, no obvious margin in 11 cases, 13 cases had a major tumor in the right lobe and a small tumor in the left lobe; 8 of 25 cases with gross invaded tissue were confirmed by histological examination, 7 of 16 cases with swollen lymph nodes were infiltrated by cancer cells.
  • CONCLUSIONS: The whole explanted liver can completely reflect the characteristics of growth and infiltration of hepatic carcinoma.
  • Attention must be paid to the small cancer lesions in another lobe, distal satellite nodes from major tumor, and tumor thrombi in a small branch of portal vein, which can not be found by imaging, and might influence the curative effectiveness after liver resection or transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Hepatectomy. Humans. Liver / pathology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21054976.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


85. Cejas P, López-Gómez M, Aguayo C, Madero R, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, Moreno García V, Larrauri J, López R, Casado E, Gonzalez-Barón M, Feliu J: KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One; 2009;4(12):e8199
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.
  • BACKGROUND: KRAS mutations in colorectal cancer primary tumors predict resistance to anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody therapy in patients with metastatic colorectal cancer, and thus represent a true indicator of EGFR pathway activation status.
  • These studies were performed using tissue samples from both the primary tumor and their related metastases (93 liver, 84%; 17 lung, 16%).
  • Mutations in KRAS were observed in 37 (34%) of primary tumors and in 40 (36%) of related metastases, yielding a 94% level of concordance (kappa index 0.86).
  • Patients with primary tumors possessing KRAS mutations had a shorter disease-free survival period after metastasis resection (12.0 vs 18.0 months; P = 0.035) than those who did not.
  • A higher percentage of KRAS mutations was detected in primary tumors of patiens with lung metastases than in patients with liver metastases (59% vs 32%; p = 0.054).
  • To further evaluate this finding we analyzed 120 additional patients with unresectable metastatic colorectal cancer who previously had their primary tumors evaluated for KRAS mutational status for clinical purposes.
  • Separately, the analysis of these 120 patients showed a tendency towards a higher degree of KRAS mutations in primary tumors of patients with lung metastases, although it did not reach statistical significance.
  • Taken together the group of 230 patients showed that KRAS was mutated significantly more often in the primary tumors of patients with lung metastases (57% vs 35%; P = 0.006).
  • CONCLUSIONS/SIGNIFICANCE: Our results suggest a role for KRAS mutations in the propensity of primary colorectal tumors to metastasize to the lung.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis


86. Kohno K, Chiba M, Murata S, Pak S, Nagai K, Yamamoto M, Yanagisawa K, Kobayashi A, Yasue H, Ohkohchi N: Identification of natural antisense transcripts involved in human colorectal cancer development. Int J Oncol; 2010 Dec;37(6):1425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of natural antisense transcripts involved in human colorectal cancer development.
  • However, involvement of NATs in colorectal cancer (CRC) development has not been reported to date.
  • Total RNAs isolated from 51 CRC tissues, 9 corresponding non-cancerous tissues and 19 liver metastatic tissues from surgically resected samples were subjected to expression analysis using a custom-microarray containing human sense/antisense probes for ca.
  • In addition, the NAT expression patterns were found to be different between primary tumors with liver metastasis and those without liver metastasis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease Progression. Female. Gene Expression Profiling. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Microarray Analysis. Middle Aged. Neoplasm Metastasis. RNA, Untranslated / genetics. RNA, Untranslated / physiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042710.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Antisense; 0 / RNA, Untranslated
  •  go-up   go-down


87. Wu MC: [Progress in diagnosis and treatment of primary liver cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug;30(4):363-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress in diagnosis and treatment of primary liver cancer].
  • The early diagnosis, surgical treatment, and comprehensive treatment of primary liver cancer (PLC) have advanced greatly in recent years.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Early Diagnosis. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795602.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


88. Capussotti L, Vigano' L, Ferrero A, Lo Tesoriere R, Ribero D, Polastri R: Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol; 2007 Mar;14(3):1143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model.
  • BACKGROUND: Timing of hepatectomy for synchronous metastases of colorectal cancer is still debated.
  • The aim of this retrospective study was to analyze prognostic factors after synchronous and delayed liver resections to define selection criteria for choosing timing of hepatectomy.
  • Patients with more than three metastases had a significantly worse survival in group A than in group B (3-year survival, 15.0% vs. 34.3%, P = .007); similarly, borderline significant difference was encountered in patients with T4 primary tumor (3-year survival, 16.7% vs. 60%, P = .064) CONCLUSIONS: Patients with liver metastases synchronous with colorectal cancer with T4 primary tumor, metastasis infiltration of neighboring structures, and especially with more than three metastases should receive neoadjuvant chemotherapy before liver resection.
  • [MeSH-major] Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Patient Selection. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 Sep;14(9):2435-6 [17562115.001]
  • (PMID = 17200913.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Ochiai T, Sonoyama T, Kikuchi S, Ikoma H, Kubota T, Nakanishi M, Ichikawa D, Kikuchi S, Fujiwara H, Okamoto K, Sakakura C, Kokuba Y, Taniguchi H, Otsuji E: Primary large gastrointestinal stromal tumor of the liver: report of a case. Surg Today; 2009;39(7):633-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large gastrointestinal stromal tumor of the liver: report of a case.
  • A histological examination of a resected liver specimen from an operation in 2002 revealed a gastrointestinal stromal tumor (GIST), diagnosed based on positive immunostaining for CD34 and c-kit.
  • Two years after the operation, new lesions developed in the residual liver and the lesser curvature of the stomach.
  • An immunohistological examination of both specimens showed the features of a GIST, thus matching those of the first histological examination of the liver GIST.
  • While there were no mutations at exon 11 of c-kit in the liver GISTs resected in 2002 and 2004, the gastric lesion had a mutation at P577L (CCT to CTT) at exon 11.
  • Therefore, the liver GIST and the gastric lesion were diagnosed to be independent.
  • [MeSH-major] Gastrointestinal Stromal Tumors / therapy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Hepatectomy. Humans. Imatinib Mesylate. Male. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Reoperation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):467-70 [15012791.001]
  • [Cites] Surg Today. 2008;38(1):65-7 [18085368.001]
  • [Cites] Am J Clin Pathol. 1993 Oct;100(4):428-32 [8105676.001]
  • [Cites] Front Biosci. 2006 Jan 01;11:498-501 [16146747.001]
  • [Cites] Surg Today. 2008;38(2):174-7 [18239881.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Arch Pathol Lab Med. 2003 Dec;127(12):1606-8 [14632569.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] J Natl Compr Canc Netw. 2004 May;2 Suppl 1:S-1-26; quiz 27-30 [23573667.001]
  • [Cites] Surg Today. 2007;37(11):953-7 [17952524.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4297-300 [10485475.001]
  • [Cites] Gastric Cancer. 2003;6(1):39-48 [12673425.001]
  • [Cites] J Pathol. 2001 Apr;193(4):505-10 [11276010.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1109-18 [10478672.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):377-89 [10199467.001]
  • (PMID = 19562456.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


90. Janković J, Ratkov I, Sipetić S, Marinković J, Maksimović J: [Oesophageal-cancer-derived death in the population of Belgrade in a period 1989-2006]. Vojnosanit Pregl; 2009 Jul;66(7):534-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oesophageal-cancer-derived death in the population of Belgrade in a period 1989-2006].
  • BACKGROUND/AIM: Oesophageal cancer is the sixth most common cause of death from all malignant tumors in the world (fifth in men, eighth in women).
  • This cancer was estimated to account for about 529 000 new cases and about 442 000 deaths in the year 2007.
  • The aim of this descriptive epidemiologic study was to analyze epidemiologic situation of oesophageal cancer in Belgrade population during the period 1989-2006, using mortality data.
  • In order to analyze trend mortality from oesophageal cancer we used linear trend.
  • RESULTS: In Belgrade deaths from oesophageal cancer accounted for about 5.2% of all malignant tumors of intestinal system in male population, and 2.4% in female population.
  • This cancer is, according to standardized mortality rates (per 100 000 habitants), on the fifth place in Belgrade population behind colorectal, stomach, pancreatic, liver and cholecystic cancer.
  • The male/female oesophageal cancer mortality ratio was 3:1.
  • Mortality rates for oesophageal cancer rise with age in both sexes and they are highest in the age group of 70 and more years.
  • Significant increase in mortality from oesophageal cancer was noticed in age groups 20-29 and over 70 in male population, and age group 40-49 in female population.
  • CONCLUSION: Increasing trend in oesophageal mortality suggests the necessity for improving measures of primary prevention including education about risk factors for this carcinoma (smoking, alcohol consumption, hot food and drinks), early diagnosis, and treatment.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Serbia / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678577.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


91. Sperti C, Pasquali C, Berselli M, Frison L, Vicario G, Pedrazzoli S: Metastasis to the pancreas from colorectal cancer: is there a place for pancreatic resection? Dis Colon Rectum; 2009 Jun;52(6):1154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the pancreas from colorectal cancer: is there a place for pancreatic resection?
  • PURPOSE: Pancreatic metastases from colorectal cancer are very rare, and the possible benefit of surgical treatment is not clearly defined.
  • This study was designed to evaluate the outcome of patients undergoing pancreatic resection for metastatic colorectal cancer to the pancreas.
  • METHODS: Nine patients underwent pancreatic resection for metastatic colorectal cancer between January 1980 and December 2006.
  • The primary cancers were colon (n = 7) and rectal carcinoma (n = 2).
  • The median interval between primary treatment and detection of pancreatic metastases was 32.5 months.
  • In three cases pancreatic metastases were synchronous with the primary tumor.
  • A left lateral liver section and three colon resections were simultaneously performed in four patients.
  • Survival averaged 19.8 (median, 17.0; range, 5-30) months: seven patients died of metastatic disease, one for unrelated disease after five months, and one is alive with liver metastases 30 months after surgery.
  • CONCLUSION: Surgical resection can be performed safely in patients with isolated pancreatic metastases from colorectal cancer and in selected patients with associated extrapancreatic disease.
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Pancreaticoduodenectomy / methods. Postoperative Complications. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome


92. Kodjikian L, Grange JD, Baldo S, Baillif S, Garweg JG, Rivoire M: Prognostic factors of liver metastases from uveal melanoma. Graefes Arch Clin Exp Ophthalmol; 2005 Oct;243(10):985-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of liver metastases from uveal melanoma.
  • OBJECTIVES: This study was designed to assess survival and identify prognostic factors for liver metastases diagnosed by systematic screening in uveal melanoma patients.
  • METHODS: Among 602 consecutive patients treated over 10 years for uveal melanoma and followed by systematic semi-annual hepatic screening (abdominal ultrasonography), 63 (10.5%) developed liver metastases; these patients form the basis of this study.
  • Factors including patient demographics, characteristics of the uveal tumor, metastasis-free interval, severity of liver metastatic involvement, and treatments of metastases were studied retrospectively regarding their prognostic value, using univariate (Kaplan-Meier method) and multivariate (Cox model) analyses.
  • RESULTS: Thirty-five patients (55.6% of the metastatic population) received systemic chemotherapy or best supportive care only; 14 patients (22.2% of the metastatic population) diagnosed with diffuse liver involvement had cytoreductive surgery and intra-arterial chemotherapy; 14 (22.2% of the metastatic population) had complete surgical removal of liver metastases followed by postoperative intra-arterial chemotherapy.
  • The median overall survival after diagnosis of liver metastases was 15 months.
  • In this cohort of 63 patients, ten or fewer preoperatively diagnosed metastases and primary uveal melanoma not involving the ciliary body were independently associated with better prognosis.
  • CONCLUSIONS: This study suggests that selected patients with screened liver metastases from uveal melanoma may benefit from aggressive treatment, including surgery.
  • [MeSH-major] Liver Neoplasms / secondary. Melanoma / secondary. Uveal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2589-95 [9215829.001]
  • [Cites] J Fr Ophtalmol. 1995;18(8-9):520-8 [7560797.001]
  • [Cites] Arch Ophthalmol. 1977 Jan;95(1):63-9 [836204.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1537-44 [9400787.001]
  • [Cites] Acta Ophthalmol Suppl. 1977;(133):1-64 [196476.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):575-9 [6861095.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1665-70 [8635073.001]
  • [Cites] Eur J Surg Oncol. 1998 Apr;24(2):127-30 [9591028.001]
  • [Cites] Ophthalmology. 1986 May;93(5):675-80 [3014416.001]
  • [Cites] South Med J. 1981 May;74(5):574-7 [7244714.001]
  • [Cites] Am J Ophthalmol. 2004 Jun;137(6):1002-10 [15183783.001]
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Ophthalmology. 1988 Jul;95(7):992-9 [2845324.001]
  • [Cites] Arch Ophthalmol. 2000 Aug;118(8):1066-70 [10922199.001]
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):334-6 [6190546.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S27-30 [9849406.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] Acta Ophthalmol Scand. 1996 Aug;74(4):315-29 [8883543.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2219-23 [7848381.001]
  • [Cites] Arch Ophthalmol. 1977 Jan;95(1):48-58 [836203.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):465-75 [12518371.001]
  • [Cites] Arch Ophthalmol. 1983 Dec;101(12):1894-9 [6651594.001]
  • [Cites] Lancet. 1996 May 4;347(9010):1222-5 [8622452.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):893-900 [15126155.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1561-8 [11013372.001]
  • [Cites] Hum Pathol. 1982 Feb;13(2):123-32 [7076200.001]
  • [Cites] Arch Ophthalmol. 1996 Sep;114(9):1101-4 [8790096.001]
  • (PMID = 15891893.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


93. Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation: A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst; 2008 Apr 16;100(8):533-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
  • A randomized trial was performed to test the impact of such dose intensification on the long-term survival of patients with small cell lung cancer (SCLC).
  • The primary outcome was 3-year survival.
  • Comparisons between response rates and toxic effects within subgroups (limited or extensive disease, liver metastases or no liver metastases, Eastern Cooperative Oncology Group performance status of 0 or 1, normal or abnormal lactate dehydrogenase levels) were also performed.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Carboplatin / administration & dosage. Carboplatin / adverse effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Incidence. Male. Middle Aged. Odds Ratio. Prognosis. Research Design. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2009 Jan 7;101(1):67; author reply 67-8 [19116385.001]
  • [CommentIn] J Natl Cancer Inst. 2008 Apr 16;100(8):520-1 [18398099.001]
  • (PMID = 18398095.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  • [Investigator] Aversa S; Brunsvig P; Buxhofer V; Crown J; De Bock R; Demirer T; Kühr T; Lange A; Leyvraz S; Martinelli G; Montes A; Piazza E; Ploner F; Rosti G; Rudolf C; Schneider CP; van Klaveren R; Yilmaz U; Parmar M; Thatcher N; Hansen H
  •  go-up   go-down


94. Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N: Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol; 2010 Apr;40(4):313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The combination chemotherapy consisting of cisplatin and etoposide, one of the standard regimens for small cell lung cancer, has been widely used to treat extrapulmonary poorly differentiated neuroendocrine carcinomas.
  • However, there were no prior reports limited to the hepatobiliary tract and pancreas as the primary sites.
  • The primary tumor site was the liver in 2 patients, gallbladder in 8 patients, pancreas in 10 patients and ampulla of Vater in 1 patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies